

**(12) PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 200037625 B2**  
**(10) Patent No. 778279**

(54) Title  
Methods and compositions for treating solid tumors

(51) <sup>6</sup> International Patent Classification(s)  
A61K 009/16 A61P 035/00

(21) Application No: 200037625 (22) Application Date: 2000.03.20

(87) WIPO No: WO00/57852

(30) Priority Data

(31) Number (32) Date (33) Country  
09/276866 1999.03.26 US

(43) Publication Date : 2000.10.16

(43) Publication Journal Date : 2000.12.21

(44) Accepted Journal Date : 2004.11.25

(71) Applicant(s)  
Guilford Pharmaceuticals, Inc.

(72) Inventor(s)  
Wenbin Dang; Robert I. Garver Jr.

(74) Agent/Attorney  
Callinan Lawrie, Private Bag 7, KEW VIC 3101

(56) Related Art  
WO 1998/048859  
WO 1998/044020  
WO 1998/044021

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  A61K 9/16, A61P 35/00		A2	(11) International Publication Number: <b>WO 00/57852</b>  (43) International Publication Date: 5 October 2000 (05.10.00)
<p>(21) International Application Number: PCT/US00/07304</p> <p>(22) International Filing Date: 20 March 2000 (20.03.00)</p> <p>(30) Priority Data: 09/276,866 26 March 1999 (26.03.99) US</p> <p>(71) Applicant (for all designated States except US): GUILFORD PHARMACEUTICALS, INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): DANG, Wenbin [CN/US]; 3304 Governor Howard Drive, Ellicott City, MD 21043 (US). GARVER, Robert, I., Jr. [US/US]; 2116 Royal Fern Lane, Hoover, AL 35244 (US).</p> <p>(74) Agent: KULIK, David, J.; Howrey Simon Arnold &amp; White, LLP, 1299 Pennsylvania Avenue, N.W., Box 34, Washington, DC 20004-2402 (US).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>	
<p>(54) Title: METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS</p> <p>(57) Abstract</p> <p>A biodegradable polymer composition comprising: (a) a poly(phosphoester) biodegradable polymer and (b) at least one antineoplastic agent in an amount effective to inhibit the growth of a solid tumor, which is suitable for intratumoral administration to treat a mammal having a solid tumor.</p>			

## METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS

## BACKGROUND OF THE INVENTION

10 1. Field of the Invention

The present invention relates to methods for treating solid tumors, in particular those pertaining to the extended release of an antineoplastic agent from biodegradable compositions.

15 2. Description of the Related Art

Antineoplastic agents, such as paclitaxel, have been used to treat solid tumors of various types. For example, those in the art have attempted to administer 20 a variety of antineoplastic agents into the tumor itself ("intraleisonally", also called "intratumorally") in the form of an aqueous slurry. See Luck et al., U.S. Patent No. 4,978,332. However, such water-based compositions also require the presence 25 of a vasoconstrictive drug to localize the action of the agent.

An opposite approach has also been taken by formulating a water immiscible, fatty acid ester matrix for intratumoral injection, e.g., of paclitaxel. See 30 WO 95/17901 published 6 July 1995 and Brown et al., U.S. Patent No. 5,573,781. However, the controlled intratumoral release of the antineoplastic agent in a lipid carrier over a prolonged period of time, for example, at least three or four weeks, has not been 35 disclosed.

Thus, there exists a need for a method of effecting the *in vivo*, controlled release of a variety of different antineoplastic agents into a solid tumor, whether they are small hydrophobic drugs, such as 40 paclitaxel, or large and bulky bio-macromolecules, such

as therapeutically useful proteins. The effective release of the antineoplastic agent preferably occurs without requiring the presence of significant amounts of a physiologically acceptable fluid vehicle, such as 5 normal saline or a water-immiscible organic solvent.

Biocompatible polymeric materials have been used in various therapeutic drug delivery and medical implant applications. If a medical implant is intended for use as a drug delivery or other controlled-release 10 system, using a biodegradable polymeric carrier is one effective means to deliver the therapeutic agent locally and in a controlled fashion, see Langer et al., "Chemical and Physical Structures of Polymers as Carriers for Controlled Release of Bioactive Agents", 15 *J. Macro. Science, Rev. Macro. Chem. Phys.*, C23(1), 61-126 (1983). In this way, less total drug is required, and toxic side effects can be minimized.

Polymers have been used for some time as carriers 20 of therapeutic agents to effect a localized and sustained release. See Leong et al., "Polymeric Controlled Drug Delivery", *Advanced Drug Delivery Rev.*, 1:199-233 (1987); Langer, "New Methods of Drug Delivery", *Science*, 249:1527-33 (1990) and Chien et al., *Novel Drug Delivery Systems* (1982). Such delivery 25 systems offer the potential of enhanced therapeutic efficacy and reduced overall toxicity. Examples of classes of synthetic polymers that have been studied as possible solid biodegradable materials include polyesters (Pitt et al., "Biodegradable Drug Delivery 30 Systems Based on Aliphatic Polyesters: Applications to Contraceptives and Narcotic Antagonists", *Controlled Release of Bioactive Materials*, 19-44 (Richard Baker ed., 1980); poly(amino acids) and pseudo-poly(amino acids) (Pulapura et al. "Trends in the Development of 35 Bioresorbable Polymers for Medical Applications", *J. Biomaterials Appl.*, 6:1, 216-50 (1992); polyurethanes

(Bruin et al., "Biodegradable Lysine Diisocyanate-based Poly(Glycolide-co- $\epsilon$  Caprolactone)-Urethane Network in Artificial Skin", *Biomaterials*, 11:4, 291-95 (1990); polyorthoesters (Heller et al., "Release of Norethindrone from Poly(Ortho Esters)", *Polymer Engineering Sci.*, 21:11, 727-31 (1981); and polyanhydrides (Leong et al., "Polyanhydrides for Controlled Release of Bioactive Agents", *Biomaterials* 7:5, 364-71 (1986).


5 More specifically, Walter et al., *Neurosurgery*, 37:6, 1129-45 (1995) discloses the use of the polyanhydride PCPP-SA as a solid carrier for intratumoral administration. Others have used 10 poly(lactic acid) as intratumoral solid carriers, for example, as needles for injection directly into the 15 lesion. See Kaetsu et al., *J. Controlled Release*, 6:249-63 (1987); and Yamada et al., U.S. Patent No. 5,304,377.

20 However, others have encountered problems with these materials. Paclitaxel has been encapsulated in poly(epsilon-caprolactone), but only about 25% of the drug was released over 6 weeks in *in vitro* assays. Dordunoo et al., "Taxol Encapsulation in Poly(epsilon-caprolactone) Microspheres", *Cancer Chemotherapy & 25 Pharmacology*, 36:279-82 (1995). Poly(lactic-co-glycolic acid) microspheres have been used for the encapsulation of paclitaxel and exhibited a relatively constant release rate over three weeks *in vitro*, but these formulations were not evaluated *in vivo*. Wang et 30 al., "Preparation and Characterization of Poly(lactic-co-glycolic acid) Microspheres for Targeted Delivery of a Novel Anticancer Agent, Taxol", *Chemical & Pharmaceutical Bulletin*, 44:1935-40 (1996). Paclitaxel has also been encapsulated in polyanhydride discs, but 35 the resulting release rate has been described as too slow for clinical utility. Park et al., "Biodegradable

polyanhydride Devices of Cefaxolin Sodium, Bupivacaine, and Taxol for Local Drug Delivery: Preparation and Kinetics and Mechanism of *in vitro* Release", *J. of Controlled Release*, 52:179-89 (1998).

5 Controlled Release, 32:175-176 (1990).

10 Polymers having phosphate linkages, called poly(phosphates), poly(phosphonates) and poly(phosphites), are known. See Penczek et al., *Handbook of Polymer Synthesis*, Chapter 17: "Phosphorus-Containing Polymers", (Hans R. Kricheldorf ed., 1992). The respective structures of these three classes of compounds, each having a different side chain connected to the phosphorus atom, are as follows:



range of biodegradation rates are attainable.

An additional feature of poly(phosphoesters) is the availability of functional side groups. Because phosphorus can be pentavalent, drug molecules or other biologically active substances can be chemically linked to the polymer. For example, drugs with -O-carboxy groups may be coupled to the phosphorus via a phosphoester bond, which is hydrolyzable. See, Leong,

U.S. Patent Nos. 5,194,581 and 5,256,765. The P-O-C group in the backbone also lowers the glass transition temperature of the polymer and, importantly, confers solubility in common organic solvents, which is desirable for easy characterization and processing.

5 Copending U.S. Patent Application Serial No.

09/053,648 filed April 2, 1998, which corresponds to PCT/US98/0681 (published October 8, 1998 as WO 98/44021), discloses biodegradable terephthalate polyester-poly(phosphate) compositions. Copending 10 Patent Application Serial No. 09/053,649 filed April 2, 1998, which corresponds to PCT/US98/06380 (published October 8, 1998 as WO 98/44020), discloses biodegradable compositions containing polymers chain-extended by phosphoesters. Further, copending 15 Application Serial No. 09/070,204 filed April 30, 1998, which corresponds to PCT/US98/09185, discloses biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds. However, 20 none of these disclosures suggests the specific use of biodegradable poly(phosphoester) compositions for the intratumoral treatment of solid tumors.

25 Thus, there remains a need for new methods and materials for the difficult problem of successfully treating tumors with a minimum of toxicity and avoiding prolonged courses of periodic re-dosing.

#### SUMMARY OF THE INVENTION

It has now been discovered that biodegradable 30 polymer compositions comprising:

(a) a poly(phosphoester) biodegradable polymer  
and  
(b) at least one antineoplastic agent in an amount effective to inhibit the growth of a 35 solid tumor

are suitable for intratumoral administration to treat a

mammal having a solid tumor. In a preferred embodiment, the composition comprises:

- (a) a poly(phosphoester) biodegradable polymer made by the process of reacting a phosphorodihalide and a diol; and
- (b) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection.

5 Alternatively, it comprises:

- (a) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection; and
  - (b) a poly(phosphoester) biodegradable polymer made by a process comprising the steps of:
    - (1) reacting at least one heterocyclic ring compound with
- H-Y-L-Y-H,  
wherein H is hydrogen;
- 20 Y is -O-, -S- or -NR<sup>4</sup>-, where R<sup>4</sup> is H or alkyl; and
- L is a divalent, branched or straight chain aliphatic group having 1-20 carbon atoms
- 25 to form a prepolymer;
- (2) further reacting the prepolymer with a phosphorodihalide to form a poly(phosphoester).

30 The invention also comprises an article suitable for the intratumoral administration of an antineoplastic agent to a mammal having a solid tumor wherein the article comprises:

- (a) a biodegradable poly(phosphoester); and
- (b) at least one antineoplastic agent in an amount effective to inhibit the growth

of said tumor when administered by intratumoral injection.

In yet another embodiment of the invention, a method is provided for treating a thoracic tumor in a mammal by the intratumoral administration of a composition comprising:

- (a) a biodegradable polymer;
- (b) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection.

An alternative method for treating a solid tumor in a mammal is by the intratumoral administration of a composition comprising:

- (a) a poly(phosphoester) biodegradable polymer;
- (b) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection.

The compositions of the invention can be used to deliver a wide variety of antineoplastic agents, for example, both hydrophobic drugs, such as paclitaxel, to large water-soluble macromolecules, such as proteins or DNAs, over an extended period of time without necessitating significant volumes of a delivery fluid or regular re-dosing. The methods of the invention can thus be used to significantly increase the time period over which an effective dose of the antineoplastic agent is released. Further, tumor growth is slowed to an unexpected degree. Further, the tumor suffered by the subject can be therapeutically managed with a minimum of side effects and without the unpleasantness and discomfort of a periodic series of parenteral treatments continuing to maintain a significant concentration of antineoplastic agent within the tumor.

## BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 shows the controlled delivery of hydrophobic small molecules, such as paclitaxel, from a film of poly(bis-hydroxyethyl terephthalate-co-ethyl phosphate/terephthalate chloride) (80:20) ["poly(BHET-EOP/TC, 80/20)"].

10 Figure 2A through 2C all show degradation data of poly(D,L-lactide-co-ethyl phosphate) ["poly(DAPG-EOP)"] polymers.

15 Figure 3 shows the time-dependent change in A549 tumor nodules treated with 24 mg/kg paclitaxel in poly(DAPG-EOP) intratumorally and treated with the poly(DAPG-EOP) carrier alone.

20 Figure 4 shows the time-dependent change in A549 tumor nodules treated intratumorally with three different dosages of paclitaxel in poly(DAPG-EOP) (4 mg/kg, 12.5 mg/kg or 24 mg/kg).

25 Figure 5 shows the time-dependent change in A549 tumor nodules treated paclitaxel in its conventional liquid formulation (24 mg/kg) via intraperitoneal administration, paclitaxel in its conventional liquid formulation (24 mg/kg) administered intratumorally, and paclitaxel in poly(DAPG-EOP) (24 mg/kg) administered intratumorally.

30 Figure 6 shows the time-dependent change in H1299 tumor nodules treated with 24 mg/kg paclitaxel in poly(DAPG-EOP) intratumorally, and the poly(DAPG-EOP) polymer carrier alone.

35 Figure 7 shows the time-dependent change in H1299 tumor nodules treated intratumorally with three different dosages of paclitaxel in poly(DAPG-EOP) (4 mg/kg, 12.5 mg/kg or 24 mg/kg).

Figure 8 shows the time-dependent change in H1299 tumor nodules treated paclitaxel in its conventional liquid formulation (24 mg/kg) via intraperitoneal administration, paclitaxel in its conventional liquid

formulation (24 mg/kg) administered intratumorally, and formulation (24 mg/kg) administered intratumorally, and paclitaxel in poly(DAPG-EOP) (24 mg/kg) administered paclitaxel in poly(DAPG-EOP) (24 mg/kg) administered intratumorally.

5 Figure 9 shows the weight changes in A549 tumor-bearing mice following treatment with either a vehicle control or 24 mg/kg of paclitaxel in its conventional liquid formulation or in poly(DAPG-EOP).

10 Figure 10 shows the weight changes in H1299 tumor-bearing mice following treatment with either a vehicle control or 24 mg/kg paclitaxel in its conventional liquid formulation or poly(DAPG-EOP).

15 Figure 11 shows estimated tumor volume doubling times based on data derived from that shown in Figures 4-6 for A549 tumor cells. P values shown represent the differences between the corresponding group and the 24 mg/kg group for paclitaxel in poly(DAPG-EOP).

20 Figure 12 shows the estimated tumor volume doubling times based on data derived from that shown in Figures 7-9 for H1299 tumor cells. P values shown represent the differences between the corresponding group and the 24 mg/kg group for paclitaxel in poly(DAPG-EOP).

#### DETAILED DESCRIPTION OF THE INVENTION

##### Polymeric Compositions of the Invention

25 As used herein, the expression "mammal" refers to any mammalian subject, such as mice, rats, guinea pigs, cats, dogs, human beings, cows, horses, sheep, or other livestock.

30 "Cancer" comprises tissue that grows by either increased cellular proliferation and/or decreased apoptosis.

35 The expression "a mammal having cancer" includes, but is not limited to, subjects suffering from current symptoms of this disease and subjects who are recovering from other modes of treatment for the

disease, such as surgery, chemotherapy, or other treatment.

As used herein, the term "treating" includes:

(i) inhibiting the disease, disorder or

condition, i.e., arresting its development;

and

(ii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

10 "Volume of tumor" means the three dimensional space occupied predominantly by a tumor in an animal as measured in cubic units.

15 "Intratumoral" administration means implanting a reservoir of a therapeutic agent(s) inside a tumor.

Intratumoral administrations is advantageous for tumor treatment because the outer cell layers of tumors are often composed of a high percentage of necrotic cells and/or connective and support tissue which slow and/or impede the extra-tumoral vascular or parenteral delivery of therapeutic agents to the actively growing cancer cells at the center of solid tumors.

20 "Doubling time" means the time it takes for a population of cancer cells to double in number of cells or the time it takes for a tumor to double its volume.

25 "Biodegradable" means capable of being biologically decomposed. A "biodegradable" polymer can be biologically decomposed into units which may be either removed from the biological system and/or chemically incorporated into the biological system.

30 Preferably, the inhibition of the growth of the solid tumor with the invention is measured as a delay in tumor doubling time. The use of the invention usually extends the doubling time significantly, preferably by a factor of at least two, more preferably by a factor of at least four and, most preferably, by a factor of

35 8-10.

Another way that the inhibition of the growth of the solid tumor with the invention is measured is as a reduction in the volume of the tumor. The use of the invention usually decreases the tumor volume significantly, preferably by at least about 10%, more preferably by at least about 30%, even more preferably by at least about 50% and, most preferably, by at least about 70%.

5 "Solid tumor" means a locus of tumor cells where the majority of the cells are tumor cells or tumor-associated cells.

10 Biodegradable polymers differ from non-biodegradable polymers in that they can be degraded during *in vivo* therapy. This generally involves breaking down the polymer into its monomeric subunits.

15 In principle, the ultimate hydrolytic breakdown products of the polymer used in the invention are a diol, an aliphatic alcohol and phosphate. All of these degradation products are potentially non-toxic.

20 However, the intermediate oligomeric products of the hydrolysis may have different properties. Thus, the toxicology of a biodegradable polymer intended for insertion into the body, even one synthesized from apparently innocuous monomeric structures, is typically determined after one or more toxicity analyses.

25 The expression "extended release", as used herein, includes, without limitation various forms of release, such as controlled release, timed release, sustained release, delayed release, long acting, and pulsatile delivery, immediate release that occurs with various rates. The ability to obtain extended release, controlled release, timed release, sustained release, delayed release, long acting, pulsatile delivery or immediate release is performed using well-known procedures and techniques available to the ordinarily skilled artisan. None of these specific techniques or

30 35

procedures constitute an inventive aspect of this invention.

The invention contemplates a biodegradable polymer composition, article, and method for treating a subject having a solid tumor. Any of a wide variety of solid tumors may respond to the treatment of the invention, including but not limited to laryngeal tumors, brain tumors, and other tumors of the head and neck; colon, rectal and prostate tumors; breast and thoracic solid tumors; ovarian and uterine tumors; tumors of the esophagus, stomach, pancreas and liver; bladder and gall bladder tumors; skin tumors such as melanomas; and the like. Moreover, the tumor treated in the invention can be either primary or a secondary tumor resulting from metastasis of cancer cells elsewhere in the body to the chest.

Preferably, the tumor is a laryngeal, colon, rectal, prostate, breast, thoracic, bladder or skin tumor. More preferably, the tumor is a thoracic tumor such as, but not limited to, bronchogenic tumors, such as primary and/or metastatic lung carcinomas [both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)]; malignant pleural effusions; or cancers of the lung parenchyma, airways, chest wall and pleural spaces. Most preferably, however, the tumor is a lung solid tumor.

The term "aliphatic" refers to a linear, branched or cyclic alkane, alkene, or alkyne. Preferred linear or branched aliphatic groups in the poly(cycloaliphatic phosphoester) composition of the invention have from about 1 to 20 carbon atoms. Preferred cycloaliphatic groups may have one or more sites of unsaturation, i.e., double or triple bonds, but are not aromatic in nature.

As used herein, the term "aryl" refers to an unsaturated cyclic carbon compound with  $4n+2 \pi$

5 electrons. As used herein, the term "heterocyclic" refers to a saturated or unsaturated ring compound having one or more atoms other than carbon in the ring, for example, nitrogen, oxygen or sulfur. "Heteroaryl" refers to a heterocyclic compound with  $4n+2$  electrons.

10 5 As used herein, the term "non-interfering substituent" means a substituent that does react with the monomers; does not catalyze, terminate or otherwise interfere with the polymerization reaction; and does not react with the resulting polymer chain through intra- or inter-molecular reactions.


15 10 The biodegradable and injectable polymer composition of the invention comprises a biodegradable poly(phosphoester) polymer. The precise poly(phosphoester) polymer used in the invention can vary widely, depending on the hydrophilicity or hydrophobicity of the antineoplastic agent used in the composition, the physical characteristics desired, and the release profile desired. Examples of useful 20 15 poly(phosphoesters) include poly(phosphates), poly(phosphites), or poly(phosphonates); poly(phosphoesters) modified with poly(carboxylic acids); poly(phenyl neocarboxylate phosphites) and poly(pentaerythritol neocarboxylate phosphites) as 25 20 described in Friedman U.S. Patent No. 3,422,982; cyclic cycloalkylene phosphates and cyclic arylene phosphates as described in Vandenberg, U.S. Patent No. 3,655,586; 30 25 substituted ethane diphosphonates as described in Kerst, U.S. Patent No. 3,664,975; polyhydroxychloropropyl phosphate-phosphates, as 35 30 described in Cohen et al., U.S. Patent No. 3,664,974; diphosphinic acid esters as described in Herwig et al., U.S. Patent No. 3,875,263; poly(phenylphosphonates), as described by Desitter et al., U.S. Patent No. 3,927,231; poly(terephthalate phosphonates), as 35 35 described by Reader, U.S. Patent No. 3,932,566;

polyamidocarboxylic acids (also called polyamic acids),  
as described by Meyer et al., U.S. Patent No.  
3,981,847; dimethyl pentaerythritol diphosphites, alkyl  
alkylene phosphites, 1,3,2-dioxaphosphorinanes, aryl  
alkylene phosphonites, and 1,3,2-oxa-aza-phospholanes,  
5 as described by Hechenbleikner, U.S. Patent No.  
4,082,897; linear saturated polyesters of phosphoric  
acid and halogenated diols, as described by Login et  
al. in U.S. Patent Nos. 4,259,222, 4,315,847 and  
10 4,315,969; polyester phosphonates based on aromatic  
dicarboxylic acids and aromatic dihydroxy compounds, as  
described by Schmidt et al., U.S. Patent Nos. 4,328,174  
and 4,374,971; polyarylene esters containing  
15 phosphorus, as described by Besecke et al., U.S. patent  
Nos. 4,463,159 and 4,472,570; polyphosphates produced  
from indan-5-ols and triphenylphosphate, as described  
in Serini et al., U.S. Patent Nos. 4,482,693 and  
4,491,656; poly(phosphoester-urethanes) as described by  
20 Leong in U.S. Patent No. 5,176,907; poly(phosphoesters)  
prepared from such compounds as bis-phenol A, as  
described by Leong in U.S. Patent Nos. 5,194,581 and  
5,256,765; and the like, the disclosures of which are  
hereby incorporated by reference.

Particularly preferred poly(phosphoesters),  
25 however, include those described in copending U.S.  
Patent Application Serial Nos. 09/053,648 filed April  
2, 1998; 09/053,649 filed April 2, 1998; and 09/070,204  
filed April 30, 1998, which correspond respectively to  
the following publications: PCT/US98/0681 (published  
30 October 8, 1998 as WO 98/44021), PCT/US98/06380  
(published October 8, 1998 as WO 98/44020) and

PCT/US98/09185, the disclosures of which are all hereby incorporated by reference.

Preferably, however, the poly(phosphoester) has the recurring monomeric units shown in formula I:



10 wherein X is -O- or -NR<sup>4</sup>-, where R<sup>4</sup> is H or alkyl, such as methyl, ethyl, 1,2-dimethylethyl, n-propyl, isopropyl, 2-methylpropyl, 2,2-dimethylpropyl or tert-butyl, n-pentyl, tert-pentyl, n-hexyl, n-heptyl and the like.

15 The group Y in formula I is -O- or -NR<sup>4</sup>-, where R<sup>4</sup> is as defined above.

20 Each of R<sup>1</sup> and R<sup>2</sup> can be any divalent organic moiety, which may be either unsubstituted or substituted with one or more non-interfering substituents, so long as the moiety and its substituents do not interfere undesirably with the polymerization, copolymerization, or biodegradation reactions of the polymer. Specifically, each of R<sup>1</sup> and R<sup>2</sup> can be a branched or straight chain aliphatic group, preferably having about 1-20 carbon atoms. For example, R<sup>1</sup> and R<sup>2</sup> can be alkylene, such as methylene, ethylene, 1-methylethylene, 1,2-dimethylethylene, n-propylene, isopropylene, 2-methylpropylene, 2,2'-dimethylpropylene or tert-butylene, n-pentylene, tert-pentylene, n-hexylene, n-heptylene, n-octylene, n-nonylene, n-decylene, n-undecylene, n-dodecylene, and the like.

25 R<sup>1</sup> and R<sup>2</sup> can also be alkenylene, such as ethenylene, propenylene, 2-vinylpropenylene, n-ethenylene, propenylene, 2-vinylpropenylene, n-pentenylene, 4-(3-but enylene, 3-ethenylbutylene, n-pentenylene, 4-(3-propenyl)hexylene, n-octenylene, 1-(4-but enyl)-3-


methyldecylene, dodecylene, 2-(3-propenyl)dodecylene, hexadecylene, and the like. R<sup>1</sup> and R<sup>2</sup> can also be alkynylene, such as ethynylene, propynylene, 3-(2-ethynyl)pentylene, n-hexynylene, octadecynylene, 2-(2-propynyl)decylene, and the like.

5 R<sup>1</sup> and R<sup>2</sup> can also be an aliphatic group, such as an alkylene, alkenylene or alkynylene group, substituted with a non-interfering substituent, for example, a hydroxy, halogen or nitrogen group.

10 Examples of such groups include, but are not limited to, 2-chloro-n-decylene, 1-hydroxy-3-ethenylbutylene, 2-propyl-6-nitro-10-dodecynylene and the like.

15 Further, R<sup>1</sup> and R<sup>2</sup> can be a cycloaliphatic group, such as cyclopentylene, 2-methylcyclopentylene, cyclohexylene, cyclohexenylene and the like. Each of R<sup>1</sup> and R<sup>2</sup> can also be a divalent aromatic group, such as phenylene, benzylene, naphthalene, phenanthrenylene, and the like, or a divalent aromatic group substituted with a non-interfering substituent. Further each of R<sup>1</sup> and R<sup>2</sup> can be a divalent heterocyclic group, such as 20 pyrrolylene, furanylene, thiophenylene, alkylene-pyrrolylene-alkylene, pyridylene, pyridinylene, pyrimidinylene and the like, or may be any of these substituted with a non-interfering substituent.

25 Preferably, R<sup>1</sup> and R<sup>2</sup> have from about 1-20 carbon atoms and are an alkylene group, a cycloaliphatic group, a phenylene group, or a divalent group having the formula:




30 wherein Z is oxygen, nitrogen, or sulfur, and m is 1 to 3. More preferably, each of R<sup>1</sup> and R<sup>2</sup> is a branched or straight chain alkylene group having from 1 to 7 carbon

atoms. Most preferably, each of R<sup>1</sup> and R<sup>2</sup> is a methylene, ethylene group, n-propylene, 2-methyl-propylene, or a 2,2'-dimethylpropylene group.

In one embodiment of the invention, either R<sup>1</sup>, R<sup>2</sup> or both R<sup>1</sup> and R<sup>2</sup>, can be an antineoplastic agent in a form capable of being released in a physiological environment. When the antineoplastic agent part of the poly(phosphoester) backbone in this way, it is released as the polymeric matrix formed by the composition of the invention degrades.

10 L in the polymer composition of the invention can be any divalent, branched or straight chain aliphatic group having 1-20 carbon atom, a cycloaliphatic group, or a group having the formula:



15

When L is a branched or straight chain alkylene group, it is preferably an alkylene group having from 1 to 7 carbon atoms, such as 2-methylmethylen or ethylene. When L is a cycloaliphatic group, it may be any divalent cycloaliphatic group so long as it does not interfere with the polymerization or biodegradation reactions of the polymer of the composition. Specific examples of useful unsubstituted and substituted cycloaliphatic L groups, include cycloalkylene groups such as cyclopentylene, 2-methylcyclopentylene, cyclohexylene, 2-chlorocyclohexylene, and the like; cycloalkenylene groups, such as cyclohexenylene; and cycloalkylene groups having fused or bridged additional ring structures on one or more sides, such as tetrailinylene, decalinylene, and norpinanylene; or the like.

R<sup>3</sup> in the polymer composition of the invention is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic and heterocycloxy residues.

When R<sup>3</sup> is alkyl or alkoxy, it preferably contains about 1 to about 20 carbon atoms, even more preferably about 1 to about 15 carbon atoms and, most preferably about 1-7 carbon atoms. Examples of such groups include methyl, methoxy, ethyl, ethoxy, n-propyl, isopropoxy, n-butoxy, t-butyl, -C<sub>2</sub>H<sub>5</sub>; alkyl substituted with a non-interfering substituent, such as halogen, alkoxy or nitro; alkyl conjugated to a biologically active substance to form a pendant drug delivery system; and the like.

When R<sup>3</sup> is aryl or the corresponding aryloxy group, it typically contains from about 5 to about 14 carbon atoms, preferably about 5 to 12 carbon atoms and, optionally, can contain one or more rings that are fused to each other. Examples of particularly suitable aromatic groups include phenyl, phenoxy, naphthyl, anthracenyl, phenanthrenyl and the like.

When R<sup>3</sup> is heterocyclic or heterocycloxy, it typically contains from about 5 to 14 ring atoms, preferably from about 5 to 12 ring atoms, and one or more heteroatoms. Examples of suitable heterocyclic groups include furan, thiophene, pyrrole, isopyrrole, 3-isopyrrole, pyrazole, 2-isoimidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, thiazole, isothiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-dioxazole, 1,2,4-dioxazole, 1,3,2-dioxazole, 1,2,3,4-dioxazole, 1,2,5-oxatriazole, 1,3-oxathiole, 1,2,1,3,4-dioxin, pyran, 1,4-pyran, 1,2-pyrone, 1,4-pyrone, 1,2-dioxin, pyridine, N-alkyl pyridinium, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, 1,2,4-triazine, 1,2,3-triazine, 1,2,4-oxazine, 1,3,2-oxazine, 1,3,5-oxazine, 1,4-oxazine, o-isoxazine, p-isoxazine, 1,2,5-

oxathiazine, 1,2,6-oxathiazine, 1,4,2-oxadiazine,  
1,3,5,2-oxadiazine, azepine, oxepin, thiepin, 1,2,4-  
diazepine, indene, isoindene, benzofuran,  
isobenzofuran, thionaphthene, isothionaphthene, indole,  
indolenine, 2-isobenzazole, 1,4-pyrindine, pyrano[3,4-  
5 indole, 2-pyrrole, isoindazole, indoxazine, benzoxazole,  
anthranil, 1,2-benzopyran, 1,2-benzopyrone, 1,4-  
benzopyrone, 2,1-benzopyrone, 2,3-benzopyrone,  
quinoline, isoquinoline, 12-benzodiazine, 1,3-  
benzodiazine, naphthpyridine, pyrido[3,4-b]-pyridine,  
10 pyrido[3,2-b]-pyridine, pyrido[4,3-b]pyridine, 1,3,2-  
benzoxazine, 1,4,2-benzoxazine, 2,3,1-benzoxazine,  
15 3,1,4-benzoxazine, 1,2-benzoxazine, 1,4-  
benzisoxazine, carbazole, xanthrene, acridine, purine,  
and the like. Preferably, when R<sup>3</sup> is heterocyclic or  
heterocycloxy, it is selected from the group consisting  
of furan, pyridine, N-alkylpyridine, 1,2,3- and 1,2,4-  
triazoles, indene, anthracene and purine rings.

20 In a particularly preferred embodiment, R<sup>3</sup> is an  
alkyl group, an alkoxy group, a phenyl group, a phenoxy  
group, or a heterocycloxy group and, even more  
preferably, an alkoxy group having from 1 to 10 carbon  
atoms. Most preferably, R<sup>3</sup> is an ethoxy or hexyloxy  
group.

25 Alternatively, the side chain R<sup>3</sup> can be the  
antineoplastic agent or some other biologically active  
substance pendently attached to the polymer backbone,  
for example by ionic or covalent bonding. In this  
30 pendant system, the antineoplastic agent or other  
biologically active substance is released as the bond  
connecting R<sup>3</sup> with the phosphorous atom is cleaved  
under physiological conditions.


35 The number of recurring monomeric units can vary  
greatly depending on the biodegradability and the  
release characteristics desired in the polymer, but  
typically varies between about 5 and 1,000.

Preferably, the number of recurring units is from about 5 to about 500 and, most preferably, is from about 5 to about 400.

When used in accordance with the method of the invention, the polymer composition provides extended release of the antineoplastic agent into the solid tumor of a subject having one or more of such tumors, preferably for a period greater than about one day. Even more preferably, the release profile extends over a time of at least about 15 days, still more preferably at least about 30 days, for example, from at least about four weeks to a year.

More preferably, however, the poly(phosphoester) polymer of the invention is a phosphoester co-ester.

In one embodiment, the biodegradable poly(phosphoester) of the invention has a molecular weight between about 2 and 500 KDaltons and comprises monomeric units represented by formulas II and III:





wherein each of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is a divalent organic moiety; and

R<sup>3</sup> is selected from the group consisting of alkoxy, aryloxy and heterocycloxy.

Even more preferably, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently an alkylene group having from 1 to 7 carbons atoms; and R<sup>3</sup> is an alkoxy group having from 1 to 7 carbon atoms. Most preferably, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of ethylene, n-propylene, 2-methylpropylene and 2,2-dimethyl-propylene; and R<sup>3</sup> is ethoxy.

In another embodiment, the polymer composition of the invention comprises a biodegradable poly(phosphoester) has a molecular weight between about

2 and 500 KDaltons and comprising monomeric units  
represented by formulas IV, V, VI and VII:



wherein X is -O- or -NR<sup>4</sup>-;

Y is -O-, -S- or -NR<sup>4</sup>-;

R<sup>4</sup> is H or alkyl;

5 M<sup>1</sup> and M<sup>2</sup> are each independently (1) a branched or straight chain aliphatic group having from 1-20 carbon atoms; or (2) a branched or straight chain, oxy-, carboxy- or amino-

10 aliphatic group having from 1-20 carbon atoms;

L is a divalent, branched or straight chain aliphatic group having 1-20 carbon atom; and

15 R<sup>3</sup> is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy.

In formulas IV-VII, the molar ratios of the various monomers to each other can vary greatly depending on the biodegradability and the release characteristics desired in the polymer but, typically, is about 1:10:1:10, respectively.

20 In formulas V and VII, each of M<sup>1</sup> and M<sup>2</sup> is preferably a branched or straight chain alkylene or alkoxylenes group, more preferably having from 1-20 carbon atoms. Even more preferably, at least one of M<sup>1</sup> and M<sup>2</sup> is an alkylene or alkoxylenes group having a

formula selected from the group consisting of  $-(\text{CH}_2)_a-$ ,

$-(\text{CH}_2)_a-\text{O}-$ , and

$-(\text{CH}_2)_a-\text{O}-(\text{CH}_2)_b-$ , wherein each of a and b is 1-7.

When either  $M^1$  or  $M^2$  is a branched or straight

chain, carboxy-aliphatic group having from 1-20 carbon

5

atoms, it can also be, for example, a divalent

carboxylic acid ester such as the divalent radical

10

corresponding to methyl formate, methyl acetate, ethyl

acetate, n-propyl acetate, isopropyl acetate, n-butyl

acetate, ethyl propionate, allyl propionate, t-butyl

15

acrylate, n-butyl butyrate, vinyl chloroacetate, 2-

methoxycarbonyl cyclohexanone, 2-acetoxycyclohexanone,

and the like. When  $M^1$  or  $M^2$  is a branched or straight

chain, carboxy-aliphatic group, it preferably has the

formula  $-\text{CHR}'-\text{CO}-\text{O}-\text{CHR}''-$ , wherein  $\text{R}'$  and  $\text{R}''$  are each

independently H, alkyl, alkoxy, aryl, aryloxy,

heterocyclic or heterocycloxy.

When either  $M^1$  or  $M^2$  is a branched or straight

chain, amino-aliphatic group having from 1-20 carbon

20

atoms, it can be a divalent amine such as  $-\text{CH}_2\text{NH}-$ ,

$-(\text{CH}_2)_2\text{N}-$ ,  $-\text{CH}_2(\text{C}_2\text{H}_5)\text{N}-$ ,  $-\text{n-C}_4\text{H}_9-\text{NH}-$ ,  $-\text{t-C}_4\text{H}_9-\text{NH}-$ ,

$-\text{CH}_2(\text{C}_2\text{H}_5)\text{N}-$ ,  $-\text{C}_2\text{H}_5(\text{C}_2\text{H}_5)\text{N}-$ ,  $-\text{CH}_2(\text{C}_6\text{H}_{11})\text{N}-$ , and the like.

When  $M^1$  or  $M^2$  is a branched or straight chain, amino-

aliphatic group, it preferably has the formula  $-(\text{CH}_2)_a-$

NR' where R' is H or lower alkyl, and "a" is from 1 to

25

7.

Preferably,  $M^1$  and/or  $M^2$  is an alkylene group

having the formula  $-\text{O}-(\text{CH}_2)_a-$  where a is 1 to 7 and,

most preferably, is a divalent ethylene group. In

30

another particularly preferred embodiment,  $M^1$  and  $M^2$  are

n-pentylene and the divalent radical corresponding to

methyl acetate respectively.

Preferably,  $R^3$  in formulas IV-VII is an alkoxy



group; X and Y are each oxygen; and  $M^1$ ,  $M^2$  and L are

each independently a branched or straight chain

35

alkylene group having from 1 to 7 carbon atoms. Still more preferably, R<sup>1</sup> is an alkoxy group having from 1 to 7 carbon atoms; L is alkylene; and M<sup>1</sup> and M<sup>2</sup> are each independently an alkylene group having from 1 to 3 carbon atoms.

5 In preferred polymers of formula VIII and IX:



wherein X, Y and R<sup>1</sup> are as defined above; M<sup>1</sup> and M<sup>2</sup> are each independently (1) a branched or straight chain aliphatic group having from about 1-20 carbon atoms, even more preferably from about 1-7 carbon atoms; or (2) a branched or straight chain, oxy-, carboxy- or amino-aliphatic group having from about 1-20 carbon atoms, such as ethoxylene, 2-methylethoxylene, propoxylene, butoxylene, pentoxylen, dodecyloxylen, hexadecyloxylen, and the like;

10 L is a divalent, branched or straight chain aliphatic group having 1-20 carbon atoms;


15 each of x and y is about 1 to 1,000;

20 the molar ratio of x:y can vary greatly depending on the biodegradability and the release characteristics desired in the polymer but, typically, is about 1;

25 the molar ratio q:r can also vary greatly depending on the biodegradability and the release characteristics desired in the polymer, but

typically varies between about 1:200 and 200:1, preferably between about 1:150 to about 150:1 and, most preferably, between about 1:99 and 99:1.

In yet another preferred embodiment, the polymer composition of the invention comprises a biodegradable poly(phosphoester) having a molecular weight between about 2 and 500 KDaltons and comprising monomeric units represented by formula X:




wherein each of  $R^1$  and  $R^2$  is independently straight or branched aliphatic, either unsubstituted or substituted with one or more non-interfering substituents; and

$L$  is a divalent cycloaliphatic group; and  
 $R^3$  is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy.

Preferably, each of  $R^1$  and  $R^2$  is a methylene group;  $R^3$  is an alkoxy group having from 1 to 6 carbon atoms; and  $L$  is cyclohexylene.

Most preferably, the biodegradable composition is suitable for intratumoral administration to treat a mammal having a thoracic solid tumor, and the composition comprises:

- (a) paclitaxel and
- (b) a biodegradable polymer having a molecular weight between about 2 and 500 KDaltons and comprising monomeric units shown in formula XI:



wherein the delay in tumor doubling time is extended by a factor of at least two. Typically, the molar ratio of x:y in formula XI is about 1:1.

The molecular weight of the polymer used in the composition of the invention can vary widely, depending on whether a rigid solid state (higher molecular weights) is desirable, or whether a flowable or flexible state (lower molecular weights) is desired. Molecular weights are determined by standard techniques well known to the ordinary skilled artisan, such as GPC and light scattering. Generally, however, weight-average molecular weights ( $M_w$ ) typically vary from about 2,000 to about 500,000 daltons, preferably from about 5,000 to about 200,000 daltons and, even more preferably, from about 5,000 to 100,000 daltons. The average molecular weight is by

One method to determine molecular weight is by combined gel permeation chromatography ("GPC") and light scattering, e.g., mixed bed columns,  $\text{CH}_2\text{Cl}_2$ , solvent, refractive index detector, and light scattering detector. Off-line  $\text{dn}/\text{dc}$  measurements are typically used.

The biodegradable polymer used in the invention is preferably sufficiently pure to be biocompatible itself and remains biocompatible upon biodegradation. By "biocompatible", it is meant that the biodegradation products or the polymer itself are non-toxic and result in only minimal tissue irritation when injected or placed into intimate contact with vasculated tissues. The requirement for biocompatibility is more easily accomplished because the presence of an organic solvent

is not required in the polymer composition of the invention.

However, the polymer used in the invention is preferably soluble in one or more common organic solvents for ease of synthesis, purification and handling. Common organic solvents include such solvents as ethanol, chloroform, dichloromethane (dimethylene chloride), acetone, ethyl acetate, DMAC, N-methyl pyrrolidone, dimethylformamide, and dimethylsulfoxide. The polymer is preferably soluble in at least one of the above solvents. The biodegradable polymer of the invention can also comprise additional biocompatible monomeric units so long as they do not interfere with the biodegradable characteristics and the desirable flow characteristics of the invention. Such additional monomeric units may offer even greater flexibility in designing the precise release profile desired for targeted drug delivery or the precise rate of biodegradability desired for other applications. When such additional monomeric units are used, however, they should be used in small enough amounts to insure the production of a biodegradable copolymer having the desired physical characteristics, such as rigidity, viscosity, flowability, flexibility or a particular morphology.


Examples of such additional biocompatible monomers include the recurring units found in other poly(phosphoesters), poly(esters), poly(lactides), poly(glycolides), poly(caprolactones), poly(anhydrides), poly(amides), poly(urethanes), poly(esteramides), poly(orthoesters), poly(dioxanones), poly(acetals), poly(ketals), poly(carbonates), poly(imino-carbonates), poly(orthocarbonates), poly(phosphazenes), poly(hydroxybutyrates), poly(hydroxyvalerates), poly(alkylene oxalates), poly(alkylene succinates), poly(malic acids),

5 poly(amino acids), poly(vinylpyrrolidone), poly(ethylene glycol), poly(hydroxycellulose), chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials. Preferably, however, a poly(phosphoester) is the major component of the composition used with the invention.

10 When additional monomeric units are used, those which have a lower degree of crystallization and are more hydrophobic are preferred. Especially preferred recurring units with the desired physical 15 characteristics are those derived from poly(lactides), poly(caprolactones), and copolymers of these with glycolide.

15 Synthesis of Poly(Phosphoester) Polymers

The most common general reaction in preparing poly(phosphates) is a dehydrochlorination between a phosphorodihalide, such as phosphorodichloride, and a diol according to the following equation:



Most poly(phosphonates) are also obtained by condensation between appropriately substituted dichlorides and diols.

25 Poly(phosphites) have been prepared from glycols in a two-step condensation reaction. A 20% molar excess of a dimethylphosphite is used to react with the glycol, followed by the removal of the methoxyphosphonyl end groups in the oligomers by high temperature and under a vacuum.

30 An advantage of melt polycondensation is that it avoids the use of solvents and large amounts of other

additives, thus making purification more straightforward. It can also provide polymers of reasonably high molecular weight. Somewhat rigorous conditions, however, are often required and can lead to chain acidolysis (or hydrolysis if water is present).  
5 Unwanted, thermally-induced side reactions, such as crosslinking reactions, can also occur if the polymer backbone is susceptible to hydrogen atom abstraction or oxidation with subsequent macroradical recombination.

10 To minimize these side reactions, the polymerization can also be carried out in solution. Solution polycondensation requires that both the prepolymer and the phosphorus component be soluble in a common solvent. Typically, a chlorinated organic solvent is used, such as chloroform, dichloromethane, or dichloroethane.  
15

20 A solution polymerization is preferably run in the presence of equimolar amounts of the reactants and a stoichiometric amount of an acid acceptor, usually a tertiary amine such as pyridine or triethylamine. Because overall milder reaction conditions can be used, side reactions are minimized, and more sensitive functional groups can be incorporated into the polymer.  
25

25 Interfacial polycondensation can be used when high reaction rates are desired. The mild conditions used minimize side reactions, and there is no need for stoichiometric equivalence between the diol and dichloride starting materials as in solution methods. The yield and molecular weight of the resulting polymer after interfacial polycondensation are affected by reaction time, molar ratio of the monomers, volume ratio of the immiscible solvents, the type of acid acceptor, and the type and concentration of the phase transfer catalyst.  
30

35 The purpose of the polymerization reaction is to form a polymer comprising (i) divalent organic

recurring units and (ii) phosphoester recurring units. The result can be a homopolymer, a relatively homogeneous copolymer, or a block copolymer. Any one of these three embodiments is well-suited for use as a controlled release medium.

5 of these in controlled release medium.


10 While the process may be in bulk, in solution, by interfacial polycondensation, or any other convenient method of polymerization, preferably, the process takes place under solution conditions. Particularly useful solvents include methylene chloride, chloroform, tetrahydrofuran, dimethyl formamide, dimethyl sulfoxide, toluene, or any of a wide variety of other inert organic solvents.


lution polymerization reaction

Particularly when solution polymerization reaction is used, an acid acceptor is advantageously present during the polymerization reaction. A particularly suitable class of acid acceptor comprises tertiary amines, such as pyridine, trimethylamine, triethylamine, substituted anilines and substituted aminopyridines. The most preferred acid acceptor is the substituted aminopyridine 4-dimethylaminopyridine ("DMAP").


In a particularly preferred embodiment of the invention, for example, the biodegradable polymer of formula VIII or IX is made by a process comprising the steps of:

25 steps of:  
(a) reacting at least one heterocyclic ring compound having formula XII, XIII or XIV:








wherein  $M^1$ ,  $M^2$  and  $X$  are as defined above,  
with an initiator having the formula:



wherein  $Y$  and  $L$  are as defined as above, to  
5 form a prepolymer of formula XV or XVI, shown  
below:



10 wherein  $X$ ,  $M^1$ ,  $M^2$ ,  $Y$ ,  $L$ ,  $R$ ,  $x$ ,  $y$ ,  $q$  and  $r$  are  
as defined above; and  
(b) further reacting the prepolymer with a  
phosphorodihalidate of formula XVII:



15 where "halo" is Br, Cl or I; and  $R^3$  is as  
defined above, to form a polymer of formula  
VIII or IX.

The function of the first reaction step (a) is to  
use the initiator to open the ring of the heterocyclic  
20 ring compound of formula XIII, XIII or XIV. Examples of  
useful heterocyclic compounds of formula XIII, XIII or

XIV include lactones, lactams, amino acid anhydrides such as glycine anhydride, cycloalkylene carbonates, dioxanones, glycolids, lactides and the like.

When the compound of the invention has formula VIII, only one heterocyclic ring compound of formula XII, which contains  $M^1$ , may be used to prepare the prepolymer in step (a). When the compound of the invention has formula IX, then a combination of a heterocyclic compound of formula XII, which contains  $M^1$ , and a heterocyclic compound of formula XIII, which contains  $M^2$  may be used in step (a). Alternatively, when the compound of the invention has formula IX, a single heterocyclic compound of formula XIV, which contains both  $M^1$  and  $M^2$  can be used in step (a).

Examples of suitable initiators include a wide variety of compounds having at least two active hydrogens ( $H-Y-L-Y-H$ ) where  $H$  is hydrogen,  $L$  is a linking group and is defined above, and  $Y$  can be  $-O-$ ,  $-S-$  or  $-NR^4$ , where  $R^4$  is as defined above. The linking group  $L$  is can be a straight chain group, e.g., alkylene, but it may also be substituted with one or more additional active-hydrogen-containing groups. For example,  $L$  may be a straight chain alkylene group substituted with one or more additional alkyl groups, each bearing a activated hydrogen moiety, such as  $-OH$ ,  $-SH$ , or  $NH_2$ . In this way, various branched polymers can be prepared using the branched active hydrogen initiators to design the resulting polymer such that it has the desired properties. However, when branched polymers are reacted with acid chlorides, cross-linked polymers will result.

The reaction step (a) can take place at widely varying temperatures, the molecular weight desired, the susceptibility of the reactants to form side reactions, and the presence of a catalyst. Preferably, however,


the reaction step (a) takes place at a temperature from about 110° to about +235°C for melt conditions. Somewhat lower temperatures may be possible with the use of either a cationic or anionic catalyst. (a) may be in bulk, in

use of either a cationic or anionic catalyst. While the reaction step (a) may be in bulk, in solution, by interfacial polycondensation, or any other convenient method of polymerization, preferably, the reaction step (a) takes place under melt conditions. Particularly useful prepolymers of

Examples of particularly useful prepolymers or


formula XVI include:  
(i)  $\text{OH}$ -terminated copolymer derived from lactide

(i) OH-terminated  
and glycolide:




(ii) OH-terminated copolymer derived from lactide and caprolactone:

and caprolactone:



35

(iii) OH-terminated copolymer derived from glycolide and caprolactone:



10 The purpose of the polymerization of step (b) is to form a polymer comprising (i) the prepolymer produced as a result of step (a) and (ii) interconnecting phosphorylated units. The result can 15 be a block or random copolymer that is particularly well-suited to use as a controlled release medium. Step (b) of the invention

15 well-suited to use as a controlled rate polymerization process.


16 The polymerization step (b) of the invention  
17 usually takes place at a lower temperature than the  
18 temperature of step (a), but also may vary widely,  
19 depending upon the type of polymerization reaction  
20 used, the presence of one or more catalysts, the  
21 molecular weight desired, and the susceptibility of the  
22 reactants to undesirable side reaction. When melt  
23 conditions are used, the temperature may vary from  
24 about 0-150°C. However, when the polymerization step  
25 (b) is carried out in a solution polymerization  
reaction, it typically takes place at a temperature  
between about -40 and 100°C.

### Antineoplastic Agent


solubility, as well as those having low water-solubility, to produce a delivery system that has controlled release rates.

The term antineoplastic agent includes, without limitation, platinum-based agents, such as carboplatin and cisplatin; nitrogen mustard alkylating agents; nitrosourea alkylating agents, such as carmustine (BCNU) and other alkylating agents; antimetabolites, such as methotrexate; purine analog antimetabolites; pyrimidine analog antimetabolites, such as fluorouracil (5-FU) and gemcitabine; hormonal antineoplastics, such as goserelin, leuprolide, and tamoxifen; natural antineoplastics, such as taxanes (e.g., docetaxel and paclitaxel), aldesleukin, interleukin-2, etoposide (VP-16), interferon alfa, and tretinoin (ATRA); antibiotic natural antineoplastics, such as bleomycin, dactinomycin, daunorubicin, doxorubicin, and mitomycin; and vinca alkaloid natural antineoplastics, such as vinblastine and vincristine.


Preferably, the antineoplastic agent is selected from the group consisting of the taxanes and other antitubullins including, but not limited to, paclitaxel, docetaxel and other synthetic taxanes. The taxanes are complex esters consisting of a 15-member taxane ring system linked to a four-member oxetan ring. In paclitaxel and docetaxel, for example, the taxane ring is linked to an ester side chain attached at the C-13 position of the ring, which is thought to be important for antitumor activity. The structures of paclitaxel and docetaxel differ in substitutions at the C-10 taxane ring position and on the ester side chain attached at C-13. Most preferably, the antineoplastic agent is paclitaxel, the structure of which is shown below with docetaxel and the precursor taxane 10-deacetyl-baccatin III.



### **Paclitaxel**



## Docetaxel



## 10-Deacetyl-baccatin III

The compound 10-deacetyl-baccatin III can be used to make a wide variety of related compounds that also exhibit antineoplastic effects.

5 Further, the following additional drugs may also be used in combination with the antineoplastic agent, even if not considered antineoplastic agents themselves: dactinomycin; daunorubicin HCl; docetaxel; doxorubicin HCl; epoetin alfa; etoposide (VP-16); 10 ganciclovir sodium; gentamicin sulfate; interferon alfa; leuprolide acetate; meperidine HCl; methadone alfa; ranitidine HCl; vinblastin sulfate; and zidovudine HCl; (AZT). For example, fluorouracil has recently been 15 formulated in conjunction with epinephrine and bovine collagen to form a particularly effective combination.

15 Still further, the following listing of amino acids, peptides, polypeptides, proteins, polysaccharides, and other large molecules may also be used: interleukins 1 through 18, including mutants and 20 analogues; interferons or cytokines, such as interferons  $\alpha$ ,  $\beta$ , and  $\gamma$ ; hormones, such as luteinizing hormone releasing hormone (LHRH) and analogues and,

gonadotropin releasing hormone (GnRH); growth factors, such as transforming growth factor- $\beta$  (TGF- $\beta$ ), fibroblast growth factor (FGF), nerve growth factor (NGF), growth hormone releasing factor (GHRF), 5 epidermal growth factor (EGF), fibroblast growth factor homologous factor (FGFHF), hepatocyte growth factor (HGF), and insulin growth factor (IGF); tumor necrosis factor- $\alpha$  &  $\beta$  (TNF- $\alpha$  &  $\beta$ ); invasion inhibiting factor-2 (IIF-2); bone morphogenetic proteins 1-7 (BMP 1-7); somatostatin; thymosin- $\alpha$ -1;  $\gamma$ -globulin; superoxide dismutase (SOD); complement factors; anti-angiogenesis factors; antigenic materials; and pro-drugs.

In a particularly preferred embodiment, the composition of the invention may comprise other biologically active substances, preferably a therapeutic drug or pro-drug, for example, other chemotherapeutic agents, antibiotics, anti-virals, anti-fungals, anti-inflammatories, vasoconstrictors and anticoagulants, antigens useful for cancer vaccine applications or corresponding pro-drugs.

Various forms of the antineoplastic agents and/or other biologically active agents may be used. These include, without limitation, such forms as uncharged molecules, molecular complexes, salts, ethers, esters, amides, and the like, which are biologically activated when implanted, injected or otherwise inserted into the tumor.

Polymer Compositions

The antineoplastic agents are used in amounts that are therapeutically effective, which varies widely depending largely on the particular antineoplastic agent being used. The amount of antineoplastic agent incorporated into the composition also depends upon the desired release profile, the concentration of the agent required for a biological effect, and the length of

time that the antineoplastic agent should be released for treatment.

There is no critical upper limit on the amount of antineoplastic agent incorporated except for that of an acceptable solution or dispersion viscosity to maintain the physical characteristics desired for the composition. The lower limit of the antineoplastic agent incorporated into the delivery system is dependent upon the activity of the drug and the length of time needed for treatment. Thus, the amount of the antineoplastic agent should not be so small that it fails to produce the desired physiological effect, nor so large that the antineoplastic agent is released in an uncontrollable manner.

Typically, within these limits, amounts of the antineoplastic agents from about 1% up to about 65%, and preferably from about 1% to about 30% by weight, can be incorporated into the present delivery systems. However, lesser amounts may be used to achieve efficacious levels of treatment for antineoplastic agent that are particularly potent.

In addition, the biodegradable polymer composition of the invention may also comprise blends of the polymer of the invention with other biocompatible polymers or copolymers, so long as the additional polymers or copolymers do not interfere undesirably with the biodegradable or mechanical characteristics of the composition. Preferably, biodegradable polymers of the present invention comprise more than about 50% of the blend. Blends of the polymer of the invention with such other polymers may offer even greater flexibility in designing the precise release profile desired for targeted drug delivery or the precise rate of biodegradability desired. Examples of such additional biocompatible polymers include other poly(phosphoesters), poly(esters), poly(lactides),

5 poly(glycolides), poly(caprolactones),  
poly(anhydrides), poly(amides), poly(urethanes),  
poly(esteramides), poly(orthoesters), poly(dioxanones),  
poly(acetals), poly(ketals), poly(carbonates),  
poly(imino-carbonates), poly(orthocarbonates),  
poly(phosphazenes), poly(hydroxybutyrates),  
poly(hydroxyvalerates), poly(alkylene oxalates),  
poly(alkylene succinates), poly(malic acids),  
poly(amino acids), poly(vinylpyrrolidone),  
10 poly(ethylene glycol), poly(hydroxycellulose), chitin,  
chitosan, and copolymers, terpolymers, or combinations  
or mixtures of the above materials.

15 Pharmaceutically acceptable polymeric carriers may  
also comprise a wide range of additional materials.  
Without limitation, such materials may include well-  
known diluents, binders and adhesives, lubricants,  
disintegrants, colorants, bulking agents, flavorings,  
sweeteners, and miscellaneous materials such as buffers  
and adsorbents, in order to prepare a particular  
20 medicated composition. The addition of such materials  
is limited to those additional materials which will not  
interfere with the biocompatibility, biodegradability  
and physical state desired of the polymer compositions  
of the invention.

25 For delivery of an antineoplastic agent or some  
other biologically active substance, the agent or  
substance is added to the polymer composition. The  
agent or substance is either dissolved to form a  
homogeneous solution of reasonably constant  
30 concentration in the polymer composition, or dispersed  
to form a suspension or dispersion within the polymer  
composition at a desired level of "loading" (grams of  
biologically active substance per grams of total  
composition including the biologically active  
substance, usually expressed as a percentage).

5 While it is possible that the biodegradable polymer or the biologically active agent may be dissolved in a small quantity of a solvent that is non-toxic to more efficiently produce an amorphous, monolithic distribution or a fine dispersion of the 10 biologically active agent in the flexible or flowable composition, it is an advantage of the invention that, in a preferred embodiment, no solvent is needed to form the desired composition.

10 The polymer composition of the invention may be a rigid solid article, a flexible solid article or material, or a flowable material. By "flowable" is meant the ability to assume, over time, the shape of the space containing it at body temperature. This 15 includes, for example, liquid compositions that are capable of being sprayed into a site; injected with a manually operated syringe fitted with, for example, a 23-gauge needle; or delivered through a catheter.

20 Also included by the term "flowable", however, are highly viscous, "gel-like" materials at room temperature that may be delivered to the desired site by pouring, squeezing from a tube, or being injected with any one of the commercially available power 25 injection devices that provide injection pressures greater than would be exerted by manual means alone for highly viscous, but still flowable, materials. Such flowable polymer compositions have the advantage of providing controllable and effective release of the antineoplastic agent over time, even in formulations containing large bio-macromolecules.

30 When the polymer used is itself flowable, the polymer composition of the invention, even when viscous, need not include a biocompatible solvent to be 35 flowable, although trace or residual amounts of biocompatible solvents may still be present. The degree of viscosity of the polymer can be adjusted by

the molecular weight of the polymer, as well as by mixing any *cis*- and *trans*-isomers of the diol in the backbone of the polymer.

5 The polymer composition of the invention can be administered by a variety of routes. For example, if flowable, it can be injected directly into the solid tumor being treated with a needle, such as a Turner Biopsy Needle or a Chiba Biopsy Needle. When treating a solid tumor in the lung, for example, the composition 10 may be administered within the thorax using bronchoscope or other device capable of cannulating the bronchial tree (e.g., from Cook Catheter Company). Masses accessible via the bronchial tree may be 15 directly injected by using one of the widely available transbronchial aspiration needles (e.g., from Milrose or Boston Scientific). The composition can also be administered within the pleural space by inserting a thoracentesis catheter or needle between the ribs into 20 the pleural space using standard thoracentesis techniques.

25 The polymer composition of the invention can also be used to produce coatings for solid devices implantable within the tumor, such as needles, rods, microparticles or stents.

25

Implants and Delivery Systems

30 In its simplest form, a biodegradable polymer delivery system consists of a solution or dispersion of an antineoplastic agent in a polymer matrix having an unstable (biodegradable) bond incorporated into the polymer backbone. In a particularly preferred embodiment, a solid article comprising the composition of the invention is inserted into the solid tumor being treated by implantation, injection, or otherwise being 35 placed within the tumor of the subject being treated.

35

for example, during or after the surgical removal of a portion of visibly cancerous tissue.

The antineoplastic agent of the composition and the polymer may form a homogeneous matrix, for example in the form of microspheres, or the antineoplastic agent may be encapsulated in some other way within the polymer. For example, the antineoplastic agent may be first encapsulated in a microsphere and then combined with the polymer in such a way that at least a portion of the microsphere structure is maintained.

10 Alternatively, the antineoplastic agent may be sufficiently immiscible in the polymer of the invention that it is dispersed as small droplets, rather than being dissolved, in the polymer.

15 As a structural medical device, the polymer compositions of the inventions provide a wide variety of physical forms having specific chemical, physical and mechanical properties suitable for insertion into the tumor being treated, in addition to being a composition that degrades in vivo into non-toxic residues. Specifically, the composition itself may be 20 fabricated to take the shape of a needle or pin that can be manually inserted into the tumor mass.

25 Biodegradable drug delivery articles can be prepared in several ways. The polymer can be melt processed using conventional extrusion or injection molding techniques, or these products can be prepared by dissolving in an appropriate solvent, followed by formation of the device, and subsequent removal of the solvent by evaporation or extraction, e.g., by spray 30 drying. By these methods, the polymers may be formed into articles of almost any size or shape desired, for example, implantable or injectable needles, rods, microspheres, or other microparticles. Typical medical articles also include coatings to be placed on other 35 implant devices.

Once inserted, the polymer composition of the invention should remain in at least partial contact with tumorous cells and the biological fluids found within tumors, such as blood and various hormones and enzymes associated with angiogenesis, and the like.

5 The implanted or injected composition will release the antineoplastic agent contained within its matrix within the tumor at a controlled rate until the substance is depleted, following the general rules for diffusion or dissolution from a rigid, flexible or flowable biodegradable polymeric matrix.

10 The method of the invention can be used to treat a solid tumor in a mammal by the intratumoral administration of a composition comprising:

15 (a) a biodegradable polymer; and  
(b) at least one antineoplastic agent in an amount effective to inhibit the growth of the tumor when administered by intratumoral injection.

20 While the method of the invention is available to treat a wide variety of solid tumors, as described above, it is particularly applicable to thoracic cancers, such as, but not limited to, bronchogenic tumors, such as primary and/or metastatic lung carcinomas (both NSCLC and SCLC); malignant pleural effusions; or non-thoracic cancers metastasizing to any site within the thorax.


25 The biodegradable polymer used in a composition to treat a thoracic tumor can comprise any biodegradable polymer, rather than being limited to poly(phosphoester) polymers. Without limitation, exemplary biodegradable polymers suitable for practicing the invention are polyanhydrides, polyesters, poly(phosphoesters), polyorthoesters, polyphosphazenes, polyesteramides, polydioxanones, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates,

poly(malic acids), poly(amino acids) and copolymers, terpolymers and combinations and mixtures of the above, and the like. Preferably, however, the biodegradable polymer comprises a poly(phosphoester).

5 The following examples are illustrative of preferred embodiments of the invention and are not to be construed as limiting the invention thereto. All polymer molecular weights are weight-average molecular weights unless otherwise indicated. All percentages are based on the percent by weight of the final 10 delivery system or formulation being prepared, unless otherwise indicated, and all totals equal 100% by weight.

#### EXAMPLES

15 Example 1: Synthesis of Copolymer Poly(BHET-EOP/TC, 80/20)



20 Under an argon stream, 10 g of 1,4-bis(hydroxyethyl) terephthalate (BHET), 9.61 g of 4-dimethylaminopyridine (DMAP), and 70 mL of methylene chloride were placed in a 250 mL flask equipped with a funnel. The solution in the flask was cooled down to

-40°C with stirring, and a solution of 5.13 g of ethyl phosphorodichloridate (EOP) (distilled before use) in 20 mL of methylene chloride was added dropwise through the funnel. After addition was complete, the mixture was stirred at room temperature for four hours to form the homopolymer BHET-EOP.

A solution of 1.60 g of terephthaloyl chloride (TC) (obtained from Aldrich Chemical Company and recrystallized with hexane before use) in 20 mL of methylene chloride was then added drop by drop. The temperature was brought up to about 45-50°C gradually, and the reaction mixture was kept refluxing overnight to complete the copolymerization of the homopolymer poly(BHET-EOP) with the additional monomer TC to form the copolymer poly(BHET-EOP/TC).

the copolymer poly(BHET-EOP/TC).  
 The solvent was then evaporated, and the residue was redissolved in about 100-200 mL of chloroform. The chloroform solution was washed with a saturated NaCl solution three times, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and quenched into ether. The resulting precipitate was redissolved in chloroform and quenched again into ether. The resulting tough, off-white solid precipitate was filtered off and dried under vacuum. Yield 82%.

The structure of poly(BHET-EOP/TC, 80/20) was ascertained by  $^1\text{H-NMR}$ ,  $^{31}\text{P-NMR}$  and FT-IR spectra. The structure was also confirmed by elemental analysis, which correlated closely with theoretical ratios. Exemplary structures may be found in published PCT application WO 98/44021.

The molecular weight of poly(BHET-EOP/TC, 80/20) was first measured by gel permeation chromatography (GPC) with polystyrene as the calibration standard. The resulting graph established a weight average molecular weight ( $M_w$ ) of about 6100 and a number average molecular weight ( $M_n$ ) of about 2200. Vapor


pressure osmometry ("VPO") for this copolymer gave an Mn value of about 7900.

Example 2: Other Diol Variations

5 Diol terephthalates that are structurally related to that of BHET were synthesized by reacting TC with either n-propylenediol or 2-methylpropylenediol, the structures of which are shown below, to form the corresponding diol terephthalate.



10



These diol terephthalates were then reacted with EOP to form the corresponding homopolymers. The homopolymers so formed were then used to produce the copolymers of the invention in a second reaction with TC.

15

Example 3: In vitro Release of Paclitaxel from Poly(BHET-EOP/TC) Copolymer

20 The polymer poly(bis-hydroxyethyl terephthalate-co-ethyl phosphate/terephthalate chloride (80:20) ["poly(BHET-EOP/TC, 80/20)"] was prepared as described above in Example 1. Both the polymer and paclitaxel were dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The solution was cast into a cold Teflon<sup>®</sup> mold, then dried under a vacuum at room 25 temperature for 48 hours. The film was then removed from the mold. Figure 1 shows paclitaxel release from the film of poly(BHET-EOP/TC, 80/20) in phosphate buffer saline at 37°C.

30


Example 4: Preparation of Poly(BHDPT-EOP/TC, 50/50) Microspheres Containing Lidocaine

5 An aqueous solution of 0.5% w/v polyvinyl alcohol (PVA) was prepared in a 600 mL beaker by combining 1.35 g of PVA with 270 mL of deionized water. The solution was stirred for one hour and filtered. A 10 copolymer/drug solution was prepared by combining 900 mg of poly(BHDPT-EOP/TC, 50/50) copolymer and 100 mg of lidocaine in 9 mL of methylene chloride and vortex-mixing.

10 While the PVA solution was being stirred at 800 rpm with an overhead mixer, the polymer/drug mixture was added dropwise. The combination was stirred for one and a half hours. The microspheres thus formed were then filtered, washed with deionized water, and lyophilized overnight. The experiment yielded 625 mg of microspheres loaded with 3.7% w/w lidocaine.

15 Lidocaine-containing microspheres were also prepared from poly(BHDPT-HOP/TC, 50/50) by the same process. This experiment yielded 676 mg of 20 microspheres loaded with 5.3% w/w lidocaine.

Example 5: Synthesis of Poly(L-lactide-co-ethyl-phosphate) [Poly(LAEG-EOP)]



P(LAEG-EOP)

5        20 g (0.139 mole of (3S)-cis-3,6-dimethyl-1,4-dioxane-2,5-dione (L-lactide) (obtained from Aldrich Chemical Company, recrystallized with ethyl acetate, sublimed, and recrystallized with ethyl acetate again) and 0.432 g (6.94 mmole) of ethylene glycol (99.8%, anhydrous, from Aldrich) were placed in a 250 mL round-bottomed flask flushed with dried argon. The flask was closed under vacuum and placed in an oven heated to 140°C. The flask was kept at this temperature for about 48 hours with occasional shaking.

10        The flask was then filled with dried argon and placed in oil bath heated to 135°C. Under an argon stream, 1.13 g of ethyl phosphorodichloridate was added with stirring. After one hour of stirring, a low vacuum (about 20 mm Hg) was applied to the system, and it was allowed to stand overnight. One hour before work-up, a high vacuum was applied. After cooling, the polymer was dissolved in 200 mL of chloroform and quenched into one liter of ether twice to an off-white


15        20

precipitate, which was dried under vacuum.  
It was confirmed by NMR spectroscopy that the polymer obtained was the desired product, poly(L-lactide-co-ethyl-phosphate) [poly(LAEG-EOP)].

5                   Example 6: Preparation of Poly(LAEG-EOP)  
                  Microspheres Containing Lidocaine  
                  Using Polyvinyl Alcohol as  
                  the Non-Solvent Phase

10                  A solution of 0.5% w/v polyvinyl alcohol (PVA) in deionized water solution was prepared in a 600 mL beaker by combining 1.05 g of PVA with 210 mL of deionized water. The solution was stirred for one hour and filtered. A polymer/drug solution was prepared by combining 630 mg of polymer and 70 mg of lidocaine in 7 mL of methylene chloride and mixing by vortex. The PVA solution was mixed at 500 rpm with an overhead mixer, and the polymer/drug solution was added dropwise. After 30 minutes of mixing, 200 mL of cold deionized water was added to the stirring PVA solution. The resulting mixture was stirred for a total of 3.5 hours. The microspheres formed were filtered off, washed with deionized water, and lyophilized overnight. Microspheres loaded with 4.2% w/w lidocaine were thus obtained.

20                  Example 7: Synthesis of Poly(DAPG-EOP)  
                  The d,l racemic mixture of poly(L-lactide-co-propyl-phosphate) ["poly(DAPG-EOP)"] was prepared as follows:



The product was obtained as a white solid soluble in organic solvents. Depending on reaction conditions, different intrinsic viscosities and different molecular weights were obtained, as shown below in summary form:

	Base(s)	Reaction Time/Temp	Eq EOPCl <sub>2</sub>	Mw	IV
5	2.5 eq TEA; 0.5 eq DMAP	15mins/ room temp.	1.05	--	0.42
	2.5 eq TEA; 0.5 eq DMAP	18hrs/ reflux	1.05	--	0.27
10	2.5 eq TEA; 0.5 eq DMAP	about 2.5 days/ reflux	1.05	--	0.39
	2.5 eq TEA; 0.1 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	--	0.06
15					
20					

Base(s)	Reaction Time/Temp	Eq EOPCl <sub>2</sub>	Mw	IV
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	91,100	0.47
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	95,900 (Mn 44,200; Mw/Mn 2.2)	0.42
1.1 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	--	0.08
1.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	--	0.23
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 17 h/room temp.	1.00	28,400	0.25
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.00	26,800 (Mn 12,900; Mw/Mn 2.1)	0.23
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	14,700	0.16
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.01	32,200 (Mn 13,000; Mw/Mn 2.5)	0.32
3.0 eq DMAP	1 h/4°C; 2 h/room temp.	1.00	--	0.20
2.5 eq TEA; 0.5 eq DMAP	1 h/4°C; 2 h/room temp.	1.00	--	0.22

30      Example 8:      Preparation of Poly(DAEG-EOP)  
 Microspheres With Lidocaine  
 Using Silicon Oil as the  
Non-solvent Phase

35      Two percent sorbitan-trioleate, which is

commercially available from Aldrich under the tradename Span-85, in silicone oil was prepared in a 400 mL beaker by combining 3 mL of Span-85 with 150 mL of silicone oil and mixing with an overhead stirrer set at 500 rpm.

5 A d,l racemic mixture of poly(L-lactide-co-ethyl-phosphate) poly(DAEG-EOP) polymer/drug solution was prepared by dissolving 400 mg of the polymer prepared by the method described above in Example 5, and 100 mg of lidocaine in 4.5 mL of methylene chloride. The 10 resulting polymer/drug solution was added dropwise to the silicone oil/span mixture with stirring. The mixture was stirred for an hour and 15 minutes. The microspheres thus formed were filtered off and washed with petroleum ether to remove the silicone oil/span mixture, and lyophilized overnight.

15 450 mg of microspheres loaded with 7.6% w/w lidocaine were thus obtained. Approximately 10 mg of microspheres were placed in phosphate buffer saline (0.1M, pH 7.4) at 37°C on a shaker and sampled regularly. The results were plotted as % lidocaine released vs. time in days.

20 Similar data for poly(DAPG-EOP) microspheres containing paclitaxel was obtained, as shown in Figures 2A, 2B and 2C.

25

Example 9: Biocompatibility of Poly(DAPG-EOP) Microspheres in Mouse Peritoneal Cavity

30

The biocompatibility of biodegradable poly(phosphoester) microspheres of the invention was tested as follows:

35

Three 30 mg/mL samples of lyophilized poly(L-lactide-co-ethyl-phosphate) microspheres were prepared by the method described above in Example 10, the first having diameters greater than 75 microns, the second having diameters within the range of 75-125 microns, and the third having diameters within the range of 125-

250 microns. Each sample was injected intra-  
5 peritoneally into a group of 18 female CD-1 mice having  
a starting body weight of 25 g. Animals in each group  
were weighed, sacrificed, and necropsied at 2, 7 and 14  
days, and at 1, 2 and 3 months. Any lesions detected  
during the necropsy were graded on a scale of 0 to 4,  
with 0 indicating no response to treatment and 4  
indicating a severe response to treatment.

10 Inflammatory lesions were observed to be  
restricted to an association with the microspheres on  
peritoneal surfaces or within fat tissue, and were  
compatible with foreign body isolation and  
encapsulation. Focal to multifocal supportive  
15 peritoneal steatitis with mesothelial hyperplasia was  
observed at 2-7 days, but gradually resolved by  
macrophage infiltration, the formation of inflammatory  
giant cells, and fibrous encapsulation of the  
microspheres at later sacrifices. Occasional adherence  
20 of microspheres to the liver and diaphragm, with  
associated inflammatory reaction, was also seen.  
Lesions related to microspheres were not seen within  
abdominal or thoracic organs. Microspheres, which were  
detected throughout the duration of the study, appeared  
25 transparent at early sacrifices but, at later times,  
developed crystalline material internally. No effects  
on body growth were observed. The peritoneal reaction  
was observed to be limited to areas directly adjacent  
to the microspheres with no apparent deleterious  
30 effects on major thoracic or abdominal organs.


Similar intraperitoneal injection of DAPG-EOP into  
male and female S-D rats gave the following results:

Dose Level	Test Material	Initial No. in Test		Cumulative Mortality <sup>a</sup>	
(mg/kg)		M	F	M	F
0	10% Dextran 40 in 0.9% Saline	25	25	0	0
30	DAPG-EOP	25	25	1	0
100	DAPG-EOP	25	25	0	0
300	DAPG-EOP	25	25	0	0

300 DAPG-EOP 25 25 0  
 \*Represents animals found dead or sacrificed  
 in moribund condition during study period.  
 M = Male; F = Female

M = Male; F = Female

15 Example 10: Synthesis of Poly(trans-CHDM-HOP)



Under an argon stream, 10 g of trans-1,4-cyclohexane dimethanol (CHDM), 1.794 g of 4-dimethylaminopyridine (DMAP), 15.25 ml (14.03 g) of N-methyl morpholine (NMM), and 50 ml of methylene chloride, were transferred into a 250 ml flask equipped with a funnel. The solution in the flask was cooled down to -15°C with stirring, and a solution of 15.19 g

of hexyl phosphorodichloridate (HOP) in 30 ml of methylene chloride was added through the funnel. The temperature of the reaction mixture was raised to the boiling point gradually and maintained at reflux temperature overnight.

5 The reaction mixture was filtered, and the filtrate was evaporated to dryness. The residue was re-dissolved in 100 ml of chloroform. This solution was washed with 0.1 M solution of a mixture of HCl and 10 NaCl, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and quenched into 500 ml of ether. The resulting flowable precipitate was 15 collected and dried under vacuum to form a clear pale yellow gelatinous polymer with the flow characteristics of a viscous syrup. The yield for this polymer was 70- 80%. The structure of poly(trans-CHDM-HOP) was ascertained by  $^{31}\text{P}$ -NMR and  $^1\text{H}$ -NMR spectra and by FT-IR spectra. The molecular weights ( $M_w=8584$ ;  $M_n=3076$ ) were determined by gel permeation chromatography (GPC) using polystyrene as a calibration standard.

20 Example 11: Incorporating Paclitaxel into Poly(CHDM-HOP) or Poly(CHDM-EOP)  
25 100 mg of each of the polymers poly(CHDM-HOP) and poly(CHDM-EOP) was dissolved in ethanol at a concentration of about 50%. After the polymer was completely dissolved, 5 mg of paclitaxel powder (a chemotherapeutic drug) was added to the solution and stirred until the powder was completely dissolved. 30 This solution was then poured into ice water to precipitate the polymer composition. The resulting suspension was centrifuged, decanted, and lyophilized overnight, to obtain a viscous gelatinous product.

Example 12: In Vitro Release of Paclitaxel from Poly(CHDM-HOP) and Poly(CHDM-EOP)

The following two polymers were prepared:  
5 Poly(CHDM-EOP) and  
Poly(CHDM-HOP)

Paclitaxel was blended with each polymer at a 10% loading level at room temperature to form a homogeneous paste. In a 1.7 mL plastic micro centrifuge tube, 5 mg of both of the paclitaxel polymer formulations to be tested was incubated with 1 mL of a buffer mixture of 80% PBS and 20% PEG 400 at 37°C. Four samples of each formulation to be tested were prepared. At specific time points, approximately every day, the PBS:PEG buffer was poured off for paclitaxel analysis by HPLC, and fresh buffer was added to the microcentrifuge tube. The release study was terminated at day 26, at which point the remaining paclitaxel in the polymer was extracted with a solvent to do a mass balance on paclitaxel.

20 When release studies for the release of paclitaxel from both polymers were performed, the total paclitaxel recovery was 65% for the poly(CHDM-HOP) formulation and 75% for the poly(CHDM-EOP) formulation.

Example 13: Preparation of p(DAPG-EOP) Microspheres Containing Paclitaxel by Solvent Dilution Method

25 30 35 A solvent dilution (evaporation) method was used in the preparation of p(DAPG-EOP) microspheres containing paclitaxel. Approximately 10 grams of paclitaxel and 90 grams of polymer were weighed and dissolved in 250 ml of ethyl acetate. To prepare the non-solvent phase, ethyl acetate (90 ml) was added to 1 liter of 0.5% PVA and homogenized for 1 minute. The drug-polymer solution and the PVA-ethyl acetate solution were transferred through an in-line

homogenizer into a flask. The solutions were stirred with an overhead stirrer. Approximately 900 ml of water was then added to the flask. The solution was then stirred for 30 minutes. The microsphere suspension was transferred to a filtering/drying unit containing 150  $\mu\text{m}$  and 25  $\mu\text{m}$  sieves. The microspheres were rinsed with one liter of de-ionized water and dried overnight. The dried microspheres on the 25  $\mu\text{m}$  sieve were collected into a container.

10                   Example 14: Preparation of p(DAPG-EOP) Microspheres Containing Paclitaxel by Solvent Evaporation Method

15                   Paclitaxel (10.08 g) and polymer (90.1 g) were weighed and dissolved in enough ethyl acetate to achieve a total volume of 250 ml. Ethyl acetate (90 ml) was added to one liter of 0.5% PVA and homogenized for 1 minute. The drug-polymer solution and the PVA-ethyl acetate solution were transferred through an inline homogenizer to a 12-liter, 3-necked flask. The solutions were stirred with an overhead stirrer. Vacuum and air were used to evaporate the ethyl acetate. The vacuum and air were turned off after 40 minutes due to excessive foaming. Stirring was continued for an additional 20 minutes. The microsphere suspension was transferred to a filtering/drying unit containing 250  $\mu\text{m}$  and 25  $\mu\text{m}$  sieves and rinsed with one liter of de-ionized water. The material left on the 25  $\mu\text{m}$  sieve was washed with de-ionized water into two one-liter centrifuge bottles and allowed to settle. After settling, the supernatant was discarded and the microspheres were frozen at -40°C for 1 hour and then lyophilized for 72 hours.

Example 15: Preparation of p(DAPG-EOP) Microspheres Containing Paclitaxel by Spray Drying Method

5           p(DAPG-EOP) is dissolved in methylene chloride at 5-20% (w/v) concentration. Paclitaxel is added to the polymer solution to achieve a final paclitaxel loading of 10% (w/w). After the drug is completely dissolved, the solution is spray dried using a Büchi spray drier. The resulting microspheres are collected.

10           Example 16: Preparation of p(DAPG-EOP) Microspheres Containing Lidocaine by Spray Drying Process

15           p(DAPG-EOP) was dissolved in methylene chloride at 5-20% (w/v) concentration. Lidocaine was added to the polymer solution to achieve a final lidocaine loading of 10% (w/w). After the drug was completely dissolved, the solution was spray dried using a Büchi spray drier. Product was collected.

20           Example 17: In Vitro Release of Paclitaxel from Poly(DAPG-EOP)

25           The in vitro release of paclitaxel from the microspheres was carried out in phosphate buffered saline (pH 7.4) at 37°C. To maintain a sink condition, an octanol layer was placed on top of the PBS to continuously extract the released paclitaxel from the aqueous phase. The released paclitaxel was quantified using an HPLC method, and the in vitro mass loss of the polymer was obtained by a gravimetric method.

30           The results are shown in Figure 2A.

Example 18: Comparative Studies of Sustained Release of Paclitaxel on A549 Tumors in an In Vivo Model

5 A murine tumor nodule model, a widely used and accepted model for investigating the efficacy of therapies for solid tumors, was used to establish the utility of sustained release for solid tumors. Athymic 10 nude Balb/c mice were engrafted with human non-small cell lung cancer cell lines (A549 and H1299, both of which were obtained from the American Type Culture Collection).

15 The cells were grown to confluence in DMEM/F12 medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum ("growth medium") under antibiotic-free conditions at 37° in a 5% CO<sub>2</sub> atmosphere. After growing under standard these tissue culture conditions, the cells were enzymatically detached, enumerated, and the concentration was adjusted as required.

20 The cells were mixed 1:1 with Matrigel™ as an enhancer for engraftment, and 2 x 10<sup>6</sup> cells were injected subcutaneously on the flanks. Tumors were allowed to grow until achieving a volume of approximately 200-400 mm<sup>3</sup>, as determined by the

25 formula:  
Tumor volume = (length) X (width) X (height)  
The dimensions of the tumor on each test animal were measured directly with calipers.

30 Various formulations of paclitaxel were administered to the test animals bearing tumors, either systemically or intratumorally. Each animal was weighed at the time of treatment so that dosages could be adjusted to achieve the mg/kg amounts reported.

35 Systemic administration was achieved by injecting the test composition into the intraperitoneal cavity of the test animal. For intraperitoneal ("IP") injections,

the animals received a total injection volume of approximately 1 mL.

Intratumoral administration ("IT"), on the other hand, was accomplished by the following procedure:

- 5 (1) injecting a single volume of about 100  $\mu$ l (0.1 mL) the test composition into the center of the tumor nodule with a 21-25 gauge needle over a time period of about 10-20 seconds;
- 10 (2) infusing the volume over about 10-15 seconds, and then leaving the needle in place for an additional time of about 10-20 seconds; and
- 15 (3) withdrawing the needle.

Following the treatments, all mice were tagged, and the tumors were measured three times weekly with calipers. Test animals were also weighed once weekly.

15 The various formulations tested were as follows:

- 20 (1) paclitaxel ("PTX") dissolved in 1:1 in 12.5% cremophor/12.5% ethanol and then diluted to the proper concentration with 0.9% NaCl (so that the injection volume was comparable for all groups), making a 115 mM solution of NaCl, ("conventional" formulation of paclitaxel); and
- 25 (2) poly(DAPG-EOP) microspheres containing 0.1 mg paclitaxel/1 mg poly (DAPG-EOP) suspended in 10% dextran 40 diluent ("PTX/Poly").

25 The results are graphically depicted in Figures 3-5 as the mean of two experiments  $\pm$ S.E.M. Figure 3 compares the results of the following treatments:

30 IP Liq Vehicle = Intraperitoneal administration of conventional cremophor/ethanol vehicle with no paclitaxel (control);

IT Liq Vehicle = Intratumoral administration of cremophor/ethanol vehicle with no paclitaxel (control);

IT Poly Vehicle = Intratumoral administration of poly(DAPG-EOP) microspheres with no paclitaxel (control); and  
IT PTX 24/Poly = Intratumoral administration of 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

5 Figure 4 compares the results of the following treatments:

10 IT PTX 4/Poly = 4 mg/kg paclitaxel in poly(DAPG-EOP) microspheres injected intratumorally;

IT PTX 12.5/Poly = 12.5 mg/kg paclitaxel in poly(DAPG-EOP) microspheres injected into tumor; and

15 IT PTX 24/Poly = 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres injected into tumor.

Figure 5 compares the results of the following treatments:

20 IP PTX 24 = Intraperitoneal injection of 24 mg/kg paclitaxel in conventional liquid formulation;

IT PTX 24 = Intratumoral injection of 24 mg/kg paclitaxel in conventional liquid formulation; and

25 IT PTX 24/Poly = Intratumoral injection of 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

30 Example 19: Comparative Studies of Sustained Release of Paclitaxel on H1299 Tumors in an In Vivo Model

35 Time-dependent changes in H1299 tumor nodule growth and/or sizes following different treatments were determined. The results are graphically depicted in Figures 6-8 as the mean of two experiments  $\pm$ S.E.M.

Figure 6 compares the results of the following treatments:

5 IP Liq Vehicle = Intraperitoneal administration of conventional cremophor/ethanol vehicle with no paclitaxel (control);

IT Liq Vehicle = Intratumoral administration of cremophor/ethanol vehicle with no paclitaxel (control);

10 IT Poly Vehicle = Intratumoral administration of poly(DAPG-EOP) microspheres with no paclitaxel (control); and

IT PTX 24/Poly = Intratumoral administration of 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

15 Figure 7 compares the results of the following treatments, all administered intratumorally:

IT PTX 4/Poly = 4 mg/kg paclitaxel in poly(DAPG-EOP) microspheres;

IT PTX 12.5/Poly = 12.5 mg/kg paclitaxel in poly(DAPG-EOP) microspheres; and

20 IT PTX 24/Poly = 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

Figure 8 compares the results of the following treatments:

25 IP PTX 24 = Intraperitoneal injection of 24 mg/kg paclitaxel in conventional liquid vehicle;

IT PTX 24 = Intratumoral injection of 24 mg/kg paclitaxel in conventional liquid vehicle;

and

30 IT PTX 24/Poly = Intratumoral injection of 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

35 Example 20: Weight Changes in Mice Following Treatment  
Animals treated with the procedures described

above in Examples 18 and 19 were weighed at Day 0, Day 7, Day 14, Day 21 and Day 28 after the following treatments:

5 IP Liq Vehicle = Intraperitoneal administration of conventional cremophor/ethanol vehicle with no paclitaxel (control);

10

IP PTX 24 = Intraperitoneal injection of 24 mg/kg paclitaxel in conventional cremophor/ethanol vehicle;

15

IT Liq Vehicle = Intratumoral administration of cremophor/ethanol vehicle with no paclitaxel (control);

20

IT PTX 24 = Intratumoral injection of 24 mg/kg paclitaxel in conventional liquid vehicle;

25

IT Poly Vehicle = Intratumoral administration of poly(DAPG-EOP) microspheres with no paclitaxel (control); and

IT PTX 24/Poly = Intratumoral injection of 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

25 The results of a single experiment are presented graphically in Figure 9 for the A549 cell line. The mean of two experiments  $\pm$  S.E.M. for the H1299 cell line is shown in Figure 10. Animal weights increased in all of the groups over time without significant differences between groups, and none of the treatment groups were associated with any overt toxicity.

30

Example 21: Tumor Doubling Time

35

Estimated tumor volume doubling times were derived from the data shown in Figures 3-8 described above. The P values shown represent the differences between the group referenced and the group receiving an intratumoral injection of 24 mg/kg paclitaxel in

poly(DAPG-EOP) microspheres. The treatments referenced are the following:

5 IP Liq Vehicle = Intraperitoneal administration of conventional cremophor/ethanol vehicle without paclitaxel (control);

IP PTX 24 = Intraperitoneal injection of 24 mg/kg paclitaxel in conventional cremophor/ethanol vehicle;

10 IT Liq Vehicle = Intratumoral injection of conventional cremophor/ethanol vehicle without paclitaxel (control);

IT PTX 4 = Intratumoral injection of 4 mg/kg paclitaxel in cremophor/ethanol vehicle;

15 IT PTX 12 = Intratumoral injection of 12 mg/kg paclitaxel in cremophor/ethanol vehicle;

IT PTX 24 = Intratumoral injection of 24 mg/kg paclitaxel in cremophor/ethanol vehicle;

IT Poly Vehicle = Intratumoral administration of poly(DAPG-EOP) microspheres with no paclitaxel (control);

20 IT PTX 4/Poly = Intratumoral injection of 4 mg/kg paclitaxel in poly(DAPG-EOP) microspheres;

IT PTX 12/Poly = Intratumoral injection of 12 mg/kg paclitaxel in poly(DAPG-EOP) microspheres;

25 IT PTX 24/Poly = Intraperitoneal injection of 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres.

30 The tumor volume doubling time was determined from the tumor measurements in all treatment groups. The results are presented graphically in Figure 11 for treating A549 cell line tumors and in Figure 12 for treating H1299 cell line tumors.

35 In the A549 cells, the doubling time of the paclitaxel in poly(DAPG-EOP) 24 mg/kg group was estimated at  $60 \pm 9.4$  days, compared to  $11.5 \pm 2.3$  days

and  $10.2 \pm 4.7$  days for the conventionally formulated paclitaxel at 24 mg/kg given by the intraperitoneal and intratumoral routes respectively. The H1299 cell doubling time in the paclitaxel/poly(DAPG-EOP) 24 mg/kg group was estimated to be  $35 \pm 8$  days, compared to  $12 \pm 1.9$  and  $11.2 \pm 1.9$  days for conventionally formulated paclitaxel (24 mg/kg) given via the intraperitoneal and intratumoral routes respectively.

In summary, tumor volume doubling times of about 60 days for A549 nodules and about 35 days for H1299 nodules for 24 mg/kg paclitaxel in poly(DAPG-EOP) microspheres, as compared with 10 and 11 days respectively in the nodules treated with the same dosage level of conventional paclitaxel by intratumoral administration.

Example 22: Efficacy Against Other Solid Tumors

Cell lines representing the following types of carcinoma are obtained from the American Type Culture Collection, amplified in culture and engrafted into immunosuppressed mice, as described above:

Cell Line	Carcinoma type
SCC-15	Head and neck
FaDu	Head and neck
HEp2	Laryngeal
WiDr	Colon
HT-29	Colon
SW 837	Rectum
SW 1463	Rectum
PC-3	Prostate
DU145	Prostate
SK-Br-3	Breast
MCF7	Breast
5637	Bladder

Cell Line	Carcinoma type
T24	Bladder
SK-MEL1	Melanoma
SK-MEL2	Melanoma

5 A series of doses of the sustained release formulation  
 of paclitaxel in poly(DAPG-EOP) microspheres at  
 different dosage levels, including some higher than 24  
 mg/kg, are administered as specified above. Tumor  
 10 volumes are followed over time. When compared with  
 test animals receiving paclitaxel in the conventional  
 cremophor/ethanol solution, the murine tumor nodule  
 model demonstrates significant improvements in  
 controlling multiple types of solid tumor growth,  
 reducing the rate of growth and, in some cases, even  
 15 reducing actual tumor size.

Example 23: Administration to Intrathoracic Masses

20 Extended release paclitaxel in poly(DAPG-EOP)  
 microspheres is administered to lung cancer tumor  
 masses, including a primary bronchogenic carcinoma and  
 a carcinoma that has metastasized to the thorax. The  
 paclitaxel-poly(DAPG-EOP) formulation is administered  
 in single or multiple doses to the lung cancer tumor  
 masses with a Turner Biopsy needle. A fluoroscope or  
 25 CT (computerized tomography) is used for guidance.  
 Dosages of 2-96 mg/kg can be used. Dosages can be  
 based on body mass or on tumor volume. A comparison to  
 intratumoral administration of the same dosage of  
 paclitaxel in a conventional cremophor/ethanol solvent  
 30 illustrate the unexpected benefits of the biodegradable  
 poly(phosphoester) compositions and methods of the  
 invention.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

5 Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof.


10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318<br

The claims defining the invention are as follows:

1. A method for treating a thoracic tumor in a mammal by the intratumoral administration of a composition comprising:
  - (a) a poly(phosphoester) polymer; and
  - 5 (b) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection.
2. A method for treating a solid tumor in a mammal by the intratumoral administration of a composition comprising:
  - (a) a poly(phosphoester) biodegradable polymer;
  - 10 (b) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection.
3. The method of claim 2 wherein the inhibition of the growth of said solid tumor is measured by a reduction in the volume of said tumor, and the amount of said antineoplastic agent is sufficient to reduce the volume of the tumor by at least 10%.
- 15 4. The method of claim 2 wherein the inhibition of the growth of said solid tumor is measured as a delay in tumor doubling time, and the tumor doubling time is extended by a factor of at least two.
5. The method of claim 2 wherein a single dose of said polymer composition provides extended release of said antineoplastic agent over a time of at least one day.
- 20 6. The method of claim 2 wherein a single dose of said polymer composition provides extended release of said antineoplastic agent over a time of at least 15 days.
7. The method of claim 2 wherein a single dose of said polymer composition provides extended release of said antineoplastic agent over a time of at least 30 days.
8. The method of claim 2 wherein said solid tumor is a non-small cell lung solid tumor.
- 25 9. The method of claim 2, wherein said antineoplastic agent comprises a taxane.
10. The method of claim 9, wherein said antineoplastic agent is paclitaxel.
11. The method of claim 2, wherein said composition further comprises a biologically active substance.
- 30 12. The method of claim 3, wherein said volume of the tumor is reduced by at least about 30%.
13. The method of claim 2, wherein said antineoplastic agent comprises an antitubullin.
14. The method of claim 13, wherein said antineoplastic agent comprises a taxane.
15. The method of claim 3, wherein said volume of the tumor is reduced by at least

about 50%.

16. The method of claim 15, wherein said antineoplastic agent comprises a taxane.
  17. The method of claim 3, wherein said volume of the tumor is reduced by at least about 70%.
  - 5 18. The method of claim 17, wherein said antineoplastic agent comprises a taxane.
  19. The method of claim 18, wherein said antineoplastic agent comprises paclitaxel.
  20. The method of claim 2, wherein said polymer is one of the following: poly(phosphates), poly(phosphites), poly(phosphonates), poly(phosphoesters) modified with poly(carboxylic acids), poly(phenyl neocarboxylate phosphites), cyclic cycloalkylene 10 phosphates, cyclic arylene phosphates, polyhydroxychloropropyl phosphate-phoshates, diphosphinic acid esters, poly(phenylphosphonates), poly(terphthalate phosphanates), poly(amidocarboxylic acids), linear saturated polyesters of phosphoric acid, polyester phosphonates, polyarylene esters containing phosphorus, or poly(phosphoester-urethanes).
  - 15 21. The method of claim 2, wherein said polymer is one of the following: poly(phosphates), poly(phosphites), or poly(phosphonates).
  22. The method of claim 21, wherein said polymer further comprises additional biocompatible monomeric units.
  23. The method of claim 2, wherein said polymer is a phosphoester co-ester.
  24. The method of claim 2, wherein said polymer comprises the monomeric units shown in formula I:



wherein


X is -O- or -NR<sup>4</sup>;

Y is -O- or -NR<sup>4</sup>;

R<sup>4</sup> is H or alkyl;

each of  $R^1$  and  $R^2$  is a divalent organic moiety;


L is a divalent, branched or straight chain aliphatic group having 1-20 carbon atoms, a cycloaliphatic group, or a group having the formula:



R<sup>3</sup> is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy.

25. The method of claim 24, wherein Y is -O-, and X is -O-.

5 26. The method of claim 2, wherein said polymer comprises the monomeric units shown in formulas II and III:



wherein each of R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> is a divalent organic moiety; and

R<sup>3</sup> is selected from the group consisting of H, alkyl, alkoxy, aryloxy and heterocycloxy.

10 27. The method of claim 26, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> are each independently an alkylene group having from 1 to 7 carbon atoms; and R<sup>3</sup> is an alkoxy group having from 1 to 7 carbon atoms.

28. The method of claim 27, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> are each independently selected from the group consisting of ethylene, n-propylene, 2-methylpropylene and 2,2-dimethylpropylene.

15 29. The method of claim 27, wherein R<sup>3</sup> is ethoxy.

30. The method of claim 26, wherein said polymer has a molecular weight between about 2 and about 500 KDaltons.

31. The method of claim 2, wherein said polymer comprises monomeric units represented by formulas IV, V, VI and VII:



25

VI

VII

wherein


X is -O- or -NR<sup>4</sup>;

Y is -O-, -S- or -NR<sup>4</sup>;

R<sup>4</sup> is H or alkyl;

- 5 M<sup>1</sup> and M<sup>2</sup> are each independently (1) a branched or straight chain aliphatic group having from 1-20 carbon atoms; or (2) a branched or straight chain, oxy-, carboxy- or amino-aliphatic group having from 1-20 carbon atoms; L is a divalent, branched or straight chain aliphatic group having 1-20 carbon atoms; and R<sup>3</sup> is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or 10 heterocycloxy.

32. The method of claim 31, wherein said polymer has the formula VIII or IX:



wherein M<sup>1</sup> and M<sup>2</sup> are each independently (1) a branched or straight chain aliphatic group having from about 1-20 carbon atoms; or (2) a branched or straight chain, oxy-, carboxy- or amino-aliphatic group having from about 1-20 carbon atoms; L is a divalent, branched or straight chain aliphatic group having 1-20 carbon atoms; the molar ratio of x:y is about one; and the molar ratio q:r varies between about 1:99 and 99:1.


33. The method of claim 32, wherein X and Y are each oxygen.

- 20 34. The method of claim 32, wherein M<sup>1</sup>, M<sup>2</sup> and L are each independently a branched or straight chain alkylene group having from 1 to 7 carbon atoms.

35. The method of claim 33, wherein R<sup>3</sup> is an alkoxy group having from 1 to 7 carbon atoms.

- 25 36. The method of claim 32, wherein R<sup>3</sup> is an alkoxy group having from 1 to 7 carbon atoms; L is alkylene; and M<sup>1</sup> and M<sup>2</sup> are each independently an alkylene group having from 1 to 3 carbon atoms.

37. The method of claim 2, wherein said polymer comprises monomeric units shown in formula XI:



wherein the molar ratio of x:y is about 1.

- 38. The method of claim 37, wherein said antineoplastic agent is paclitaxel.
- 39. The method of claim 38, wherein said solid tumor is a thoracic tumor.
- 5 40. The method of claim 2, wherein said solid tumor is a thoracic tumor.
- 41. The method of claim 2, wherein said solid tumor is a lung solid tumor.
- 42. The method of claim 38, wherein said solid tumor is a lung solid tumor.
- 43. The method of claim 2, wherein said composition further comprises a pharmaceutically acceptable polymeric carrier.
- 10 44. The method of claim 2, wherein said composition is about 1% to about 65% by weight antineoplastic agent.
- 45. The method of claim 2, wherein said composition is about 1% to about 30% by weight antineoplastic agent.
- 46. The method of claim 2, wherein said composition is administered in single or multiple doses.
- 15 47. The method of claim 45, wherein said antineoplastic agent is paclitaxel.
- 48. The method of claim 1, wherein said antineoplastic agent is selected from the group consisting of platinum-based agents, nitrogen mustard alkylating agents, nitrosourea alkylating agents, antimetabolites, purine analog antimetabolites, hormonal antineoplastics, natural antineoplastics, antibiotic natural antineoplastics, and vinca alkaloid natural antineoplastics.
- 20 49. The method of claim 48, wherein said antineoplastic agent is selected from the group consisting of taxanes and antitubullins.
- 50. The method of claim 1, wherein said antineoplastic agent is paclitaxel.
- 25 51. The method of claim 1, wherein said thoracic tumor is a lung solid tumor.
- 52. The method of claim 1, wherein the inhibition of the growth of said thoracic tumor is measured by a reduction in the volume of said tumor, and the amount of said antineoplastic agent is sufficient to reduce the volume of the tumor by at least 10%.
- 53. The method of claim 1, wherein the inhibition of the growth of said thoracic tumor is measured as a delay in tumor doubling time, and the tumor doubling time is extended by

a factor of at least two.

54. The method of claim 1, wherein a single dose of said polymer composition provides extended release of said antineoplastic agent over a time of at least one day.

55. The method of claim 1, wherein a single dose of said polymer composition provides extended release of said antineoplastic agent over a time of at least 15 days.

56. The method of claim 1, wherein a single dose of said polymer composition provides extended release of said antineoplastic agent over a time of at least 30 days.

57. The method of claim 1, wherein said composition is administered in single or multiple doses.

10 58. The method of claim 1, wherein said composition further comprises a pharmaceutically acceptable polymeric carrier.

59. The method of claim 1, wherein said composition is about 1% to about 65% by weight antineoplastic agent.

60. The method of claim 1, wherein said composition is about 1% to about 30% by weight antineoplastic agent.

61. The method of claim 1, wherein said composition is flowable.


62. The method of claim 2, wherein said composition is flowable.

63. The method of claim 1, wherein said composition is in the form of microspheres.

64. The method of claim 32, wherein said composition is in the form of microspheres.

20 65. A method for treating a solid tumor in a mammal by the intratumoral administration of a composition comprising:

(a) a polymer comprises monomeric units shown in formula XI:



wherein the molar ratio of x:y is about 1; and

25 (b) at least one antineoplastic agent in an amount effective to inhibit the growth of said tumor when administered by intratumoral injection.

66. The method of claim 65, wherein said antineoplastic agent is a taxane.

67. The method of claim 66, wherein said antineoplastic agent is paclitaxel.

68. The method of claim 1 substantially as hereinbefore described in any one of the Examples.

5

DATED this 30<sup>th</sup> day of September, 2004

**GUILFORD PHARMACEUTICALS, INC.**

10 By their Patent Attorneys:  
CALLINAN LAWRIE



30  
SEP  
2004  
J. M.  
CALLINAN

16/09/04,at12345 claims,74

---

1/12




FIG.1




FIG.2A

SUBSTITUTE SHEET (RULE 26)

2/12




FIG.2B




FIG.2C

SUBSTITUTE SHEET (RULE 26)

3/12




FIG.3

SUBSTITUTE SHEET (RULE 26)

4/12




FIG. 4

SUBSTITUTE SHEET (RULE 26)

5/12




FIG.5

SUBSTITUTE SHEET (RULE 26)

6/12




FIG. 6

SUBSTITUTE SHEET (RULE 26)

7/12




FIG.7

SUBSTITUTE SHEET (RULE 26)

8/12




FIG. 8

SUBSTITUTE SHEET (RULE 26)




FIG. 9





FIG. 10

11/12



SUBSTITUTE SHEET (RULE 26)

12/12




FIG.12

SUBSTITUTE SHEET (RULE 26)